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The tumor microenvironment is a crucial factor in breast tumorigenesis. Tumor 
epithelial cells maintain 3D structure in tumor stroma and they interact with soluble 
factors secreted by stromal cells such as cancer associated fibroblasts (CAFs) or directly 
with the extracellular matrix (ECM). Recent studies have shown that the hormone 
prolactin (PRL) promotes the proliferation and survival of breast cancer cells in part via 
the transactivation of human epidermal growth factor receptor 2 (HER2), also known as 
Neu in rodents.  A PRL receptor (PRLR) antagonist, G129R, has been demonstrated not 
only to be able to directly inhibit PRLR activation but also indirectly inhibits the tyrosine 
phosphorylation of HER2 (p-HER2) in human breast cancer cell lines.  However, there is 
an obvious discrepancy related to the inhibitory effects of G129R on p-HER2 between 
the monolayer cell culture system and i  vivo.   
In this dissertation, I investigated the potential mechanisms by which tumor 
stroma exert upon the cross talk between PRLR and HER2/Neu. To compare drug 
response to G129R between tumors and primary cultured cells, mammary tu ors were 
resected and cultured as small tumor chunks (≈3 mm3) or were cultured in monolayer.  
G129R reduced p-Neu in a dose-dependent manner (IC50 ≈10 µg/ml) in tumor chunks, 
but had no significant effect upon primary tumor epithelial cells grown in monolayer.  
Similar to that observed in mouse tumor chunks, direct co-culture of mouse tumor 
epithelial cells with CAFs restored the response of epithelial cells to G129R.  The 
addition of PRL, as expected, induced p-Neu in both the tumor chunk and co-culture 
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models.  The inhibitory effect of G129R was absent when CAFs were physically 
separated from mouse tumor epithelial cells using a transwell system, or when CAFs 
were replaced with normal fibroblasts in direct co-culture with human or mouse tumor 
epithelial cells.  In human breast cancer cell lines, the activation of HER2 was reduced by 
G129R when co-cultured with mouse or human CAFs.  Furthermore, 3D culture of just 
mouse or human tumor epithelial cells with ECM components restored the sam  response 
to both G129R and PRL, suggesting that ECM components or 3D cell structure at least 
partially contributes to the cross talk between HER2/Neu and PRLR in breast cancer. 
Finally, G129R was tested in ex vivo and in vivo models. I demonstrated that G129R had 
an additive inhibitory effect on p-Neu in tumor chunks when combined with lapatinib, a 
HER1 and HER2/Neu tyrosine kinase inhibitor. Also, it reduced tyrosine phosphorylation 
of Neu (p-Neu) in primary mammary tumors of mice in a time- and dose-dependent 
manner. 
In conclusion, tumor stroma play a critical role in modulating the cross talk 
between PRLR and HER2/Neu in both human and mouse models of breast cancer.  The 
inhibitory effects of G129R on p-HER2/Neu are dependent, at least in part, upon 
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Cancer is known as malignant neoplasm, the growth of which is incoordinate with 
the surrounding normal tissues and that persists in the absence of the inciting stimulus.  
There are more than 100 distinct types of cancer, and subtypes of tum rs can be found 
within specific organs [197]. 
In 2008, approximately 12.7 million cancers were diagnosed (excluding non-
melanoma skin cancers and other non-invasive cancers) and 7.6 million people died of 
cancer worldwide [147].  Cancers as a group account for approximately 13% of all deaths 
each year with the most common being:  lung cancer (1.4 million deaths), stomach cancer 
(740,000 deaths), liver cancer (700,000 deaths), colorectal cancer (610,000 deaths), and 
breast cancer (460,000 deaths).  This makes invasive cancer the leading cause of death in 
the developed world and the second leading cause of death in the developing world [294]. 
Only 5-10% of all cancer cases can be attributed to genetic defe ts, whereas the 
remaining 90-95% have their roots in the environment and lifestyle [294].  These risk 
factors include cigarette smoking, diet (fried foods, red meat), alcohol, sun exposure, 
environmental pollutants, infections, stress, obesity, and physical inactiv ty [294].  The 
evidence indicates that of all cancer-related deaths, almost 25-30% are due to tobacco, as 
many as 30-35% are linked to diet, about 15-20% are due to infections, and the remaining 
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percentage are due to other factors like radiation, stress, physical activity, environmental 
pollutants [294].  All the risk factors directly damage genes or combine with existing 
genetic faults within cells to cause the disease [161]. 
Hallmarks of Cancer 
Cancer arises from normal tissues and it is fundamentally a dise se of failure of 
regulation of tissue growth [291].  Histopathology and genomic studies have provided 
evidence that cancer progression is a multi-step process in which a somatic cell first 
undergoes an initiating event (e.g. environmental damage) and then a second or 
promoting event such as loss of heterogeneity.  The accumulation of ge etic alterations is 
thought to drive cancer progression [291].  A carcinogen or mutagen, for instance from 
alcohol, when drunk in sufficient quantity and duration may act to form an unwanted 
bond on DNA and potentially mutating a gene [125].  Also, many cancers will develop as 
a result of a chronic inflammatory state due to infections [195]. 
Weinberg et al. suggested that all of the cancer cell genotypes were a 
manifestation of six essential alterations in cell physiology that collectively dictated 





Fig.1.1  The hallmarks of cancer 
This illustration encompasses the six hallmark capabilities [126]. 
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(anti-growth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (Fig.1.1).  They 
proposed that these six capabilities were shared in common by most and perhaps all types 
of human tumors [125]. 
Recently, Weinberg et al. introduced two additional hallmarks of cancer involved 
in the pathogenesis of cancers.  One involves the capability to modify, or reprogram, 
cellular metabolism in order to most effectively support neoplastic proliferation.  The 
second allows cancer cells to evade immunological destruction, in partcular by T and B 
lymphocytes, macrophages, and natural killer cells [126]. 
Sustaining proliferative signaling 
Normal tissues control the production and release of growth-promoting sig als 
through the cell growth and division cycle, thereby ensuring a homeostasis of cell number 
and maintenance of normal tissue architecture and function.  Cancer cells, du  to the 
disruption in these signals, transform into cells under their own control.  The enabling 
signals are conveyed in large part by growth factors that bind cell-surface receptors, 
typically containing intracellular tyrosine kinase domains.  The latter subsequently 
transmits signals via branched intracellular signaling pathways that regulate progression 
through the cell cycle as well as cell growth; often these signals influence yet other cell-
biological properties, such as cell survival and energy metabolism [126]. 
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Somatic mutations activate additional downstream pathways. DNA sequencing 
analyses of cancer cell genomes have revealed somatic mutations in certain human 
tumors that predict constitutive activation of signaling pathways usually triggered by 
activated growth factor receptors.  Approximately 40% of human melanom s contain 
activating mutations affecting the structure of the B-RAF protein, r sulting in constitutive 
signaling through the RAF to mitogen activated protein kinase (MAPK) pathway [67].  
Similarly, mutations in the catalytic subunit of phosphoinositide 3-kinase (PI3K) 
isoforms are being detected in an array of tumor types, which serve to overactivate the 
PI3K signaling pathway, including its key AKT/PKB signal transducer [148, 311].  The 
advantages to tumor cells of activating upstream (receptor) versus downstream 
(transducer) signaling remain obscure, as does the significance of cross talk between the 
multiple pathways from growth factor receptors [126]. 
Negative-feedback mechanisms in proliferative signaling are disrupted to tumors.  
Recent results have highlighted the importance of negative feedback th t normally 
operate to suppress various types of signaling and thereby ensure homeostatic regulation 
of the intracellular signals [42, 292].  Defects in these feedback mechanisms are in turn 
enhancing proliferative signaling.  This type of regulation involves the RAS oncoprotein: 
the oncogenic effects of RAS result from the compromised RAS GTPase activity, which 
operates as an intrinsic negative-feedback mechanism that normally ensures active signal 
transmission is short-term only. A prominent example involves the PTEN phosphatase, 
which counteracts PI3K by degrading its product, phosphatidylinositol tr sphosphate 
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(PIP3).  Yet another example involves the mTOR kinase, a coordinator of cell growth and 
metabolism that lies both upstream and downstream of the PI3K pathway [216, 266].  
Evading growth suppressors 
Cancer cells must circumvent programs that negatively regulate cell proliferation; 
many of these programs depend on the actions of tumor suppressor genes.  Tumor 
suppressors operate in various ways to limit cell growth and proliferation.  The two most 
common tumor suppressors encode the retinoblastoma-associated protein (RB) a d tumor 
protein 53 (TP53).  The RB protein integrates signals from diverse xtracellular and 
intracellular sources and, in response, decides whether or not a cell should proceed 
through its growth-and-division cycle [41].  Cancer cells with defects in RB pathway 
function are thus missing the services of a critical gatekeeper of cell-cycle progression 
whose absence permits persistent cell proliferation.  Whereas RB transduces growth-
inhibitory signals that originate largely outside of the cell, TP53 receives inputs from 
stress and abnormality sensors that function within the cell’s intracellular operating 
systems:  if the degree of damage to the genome is excessive, or if the levels of 
nucleotide, growth-promoting signals, glucose, or oxygenation are abnormal, TP53 can 
pause further cell-cycle progression until these conditions have been normalized [126]. 
Apoptosis, the programmed cell death is triggered in response to various 
physiologic stresses that cancer cells experience during the course of carcinogenesis.  It is 
attenuated in those tumors that succeed in progressing to states of high-grade malignancy 
and resistance to therapy [2].  The apoptotic program is composed of both upstream 
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regulators such as Fas ligand/Fas receptor and downstream effector components like 
caspases 8 and 9, which proceeds to initiate a cascade of proteolysis, in which the cell is 
progressively disassembled and then consumed, both by its neighbors and by phagocytic 
cells [2].  Tumor cells develop a variety of strategies to limit or circumvent apoptosis.  
Most common is the loss of TP53 tumor suppressor function, which eliminates this 
critical damage sensor from the apoptotic program.  Alternatively, tumors may achieve 
similar ends by increasing expression of anti-apoptotic regulators (Bcl-2) or of survival 
signals (IGF1/2), by down-regulating pro-apoptotic factors (Bax, im), or by interrupting 
the extrinsic ligand-induced death pathway.  The multiplicity of apoptosis-avoiding 
mechanisms presumably reflects the diversity of apoptosis-inducing sig als that cancer 
cell populations encounter during their evolution to the malignant state [126]. 
Autophagy mediates both tumor cell survival and death.  Autophagy represents an 
important physiologic response that normally operates at low levels in cells but can be 
strongly induced in certain states of cellular stress, the mostobvious of which is nutrient 
deficiency [182, 199]. The autophagic program enables cells to break down cellular 
organelles, such as ribosomes and mitochondria, allowing the resulting catabolites to be 
recycled and thus used for biosynthesis and energy metabolism.  As a re ult, low 
molecular-weight metabolites are generated to support survival in the stressed, nutrient-
limited environments experienced by many cancer cells.  Like apoptosis, he autophagy 
machinery has both regulatory and effector components [199].  They are proteins that 
mediate autophagosome formation and delivery to lysosomes.  The signaling p thways 
involve the PI3K, AKT, and mTOR kinases [199]. For instance, mice bearing inactivated 
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alleles of the Beclin-1 gene or of certain other components of the autophagy machinery 
exhibit increased susceptibility to cancer [199].  These results sugge t that induction of 
autophagy can serve as a barrier to tumorigenesis that may operate independently of or in 
concert with apoptosis [293]. 
Necrosis has pro-inflammatory and tumor-promoting potential.  In contrast o 
apoptosis, in which a dying cell contracts into an almost-invisible corpse, necrotic cells 
become bloated and explode, releasing their contents into the local tissue.  Necrotic cell 
death releases pro-inflammatory signals into the surrounding tissue.  As a consequence, 
necrotic cells can activate the immune system [104]. Evidence indicates that immune 
inflammatory cells can be actively tumor promoting, given that such cells are capable of 
inducing angiogenesis, cancer cell proliferation, and invasiveness.  Additionally, necrotic 
cells can release bioactive regulatory factors, such as IL-1, which can directly stimulate 
neighboring cells to proliferate, with the potential to facilitate neoplastic progression 
[119].  Consequently, necrotic cell death, while seemingly beneficial in counterbalancing 
cancer-associated hyperproliferation, may ultimately do more damage than good [126]. 
Enabling replicative immortality 
Multiple lines of evidence indicate that telomeres protecting the ends of 
chromosomes are involved in the capability for unlimited proliferation [240].  The 
telomeres, composed of multiple tandem hexanucleotide repeats, shorten pr gressively in 
non-immortalized cells, eventually losing the ability to protect the ends of chromosomal 
DNAs from end-to-end fusions; such fusions generate unstable chromosomes whose 
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resolution results in the loss of cell viability.  Accordingly, the length of telomeric DNA 
in a cell dictates how many successive cell generations its progeny can pass through 
before telomeres are largely eroded and have consequently lost their prot ctive functions, 
triggering cell death.  Telomerase, the specialized DNA polymerase that adds telomere 
repeat segments to the ends of telomeric DNA, is almost absent in non-immortalized cells 
but expressed at significant levels in 90% of spontaneously immortalized cells, including 
human cancer cells.  By extending telomeric DNA, telomerase is able to counter the 
progressive telomere erosion.  The presence of telomerase activity, either in 
spontaneously immortalized cells or in the context of cells engineered to express the 
enzyme, is correlated with a resistance to induction of cell senesc nce.  The eventual 
immortalization of cells that proceed to form tumors has been attributed to their ability to 
maintain telomeric DNA at lengths sufficient to avoid triggering senescence, achieved 
most commonly by up-regulating expression of telomerase or, less fr quently, via an 
alternative recombination-based telomere maintenance mechanism [126]. 
Inducing angiogenesis 
Like normal tissues, tumors require sustenance in the form of nutrie ts and 
oxygen as well as an ability to evacuate metabolic wastes and carbon dioxide.  The 
tumor-associated neovasculature, generated by the process of angigenesis, addresses 
these needs.  During tumor progression, an angiogenic switch is almo t always activated, 
causing normal vasculature to continually generate new vessels that help sustain 
expanding neoplastic growths [124]. 
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The blood vessels produced within tumors by chronically activated angiogenesis 
are typically aberrant: tumor neovasculature is marked by precocious capillary sprouting, 
convoluted and excessive vessel branching, distorted and enlarged vessels, rratic blood 
flow, microhemorrhages, leakiness, and abnormal levels of endothelial cel  proliferation 
and apoptosis [14, 210]. 
Observations suggest an initial angiogenic switch takes place during tumor 
development followed by a variable intensity of ongoing neovascularization [13].  Of 
note, the switching mechanism can vary in its form, even though the net resul is a 
common inductive signal (e.g., VEGF).  In some tumors, dominant oncogenes operating 
within tumor cells, such as RAS and Myc, can up-regulate expression of angiogenic 
factors, whereas in others, such signals are produced indirectly by immune inflammatory 
cells, such as macrophages, neutrophils, mast cells, and myeloid progenitors. 
Additionally, pericyte coverage is also important for the maintenance of a functional 
tumor neovasculature [24]. 
Activating invasion and metastasis 
The multistep process of invasion and metastasis has been described as a 
sequence of many steps, often termed the invasion-metastasis cascade [268].  It is a 
succession of cell-biologic changes, beginning with local invasion, then intravasation by 
cancer cells into nearby blood and lymphatic vessels, transit of cancer cells through the 
lymphatic and hematogenous systems, followed by escape of cancer cells from the 
lumina of such vessels into the parenchyma of distant tissues (extravasation), the 
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formation of small nodules of cancer cells (micrometastases), and finally the growth of 
micrometastatic lesions into macroscopic tumors, this last step b ing termed 
“colonization” [126].  Thus, overall, metastasis can be broken down into two maj r 
phases: the physical dissemination of cancer cells from the primary tumor to distant 
tissues, and the adaptation of these cells to foreign tissue microenvironments that results 
in successful colonization, i.e., the growth of micrometastases into macroscopic tumors 
[126]. 
The down-regulation and occasional mutational inactivation of E-cadherin in 
human carcinomas provided strong support for its role as a key suppressor of this 
hallmark capability [28].  A developmental regulatory program, refer d to as the 
epithelial-mesenchymal transition(EMT), has become implicated s a means by which 
transformed epithelial cells can acquire the abilities to invade, to resist apoptosis, and to 
disseminate [166, 230].  A set of transcriptional factors, including Snail, Slug, Twist, and 
Zeb1/2, participate in the EMT and related migratory processes during embryogenesis; 
most were initially identified by developmental genetics.  These transcriptional regulators 
are expressed in various combinations in a number of malignant tumor types and have 
been shown in experimental models of carcinoma formation to be important for 
programming invasion [307]. 
Furthermore, cross talk between cancer cells and cells of the tumor stroma is also 
involved in the acquired capability for invasive growth and metastasis [84].  For example, 
mesenchymal stem cells (MSCs) present in the tumor stroma have been found to secrete 
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CCL5 in response to signals released by cancer cells; CCL5 then acts reciprocally on the 
cancer cells to stimulate invasive behavior [155].  Macrophages at thetumor stroma can 
foster local invasion by supplying matrix-degrading enzymes such as metalloproteinases 
and cysteine cathepsin proteases [158].  And in an experimental model of metastatic 
breast cancer, tumor-associated macrophages (TAMs) supply epidermal growth factor 
(EGF) to breast cancer cells, while the cancer cells reciprocally stimulate the 
macrophages with CSF-1; their concerted interactions facilitate invasion into the 
circulatory system and metastatic dissemination of the cancer cells [233]. 
An emerging hallmark:  reprogramming energy metabolism 
The chronic and uncontrolled cell proliferation in cancer involves not only 
deregulated control of cell proliferation but also corresponding adjustments of energy 
metabolism in order to fuel cell growth and division.  Otto Warburg first observed an 
anomalous characteristic of cancer cell energy metabolism:  even in the presence of 
oxygen, cancer cells can reprogram their glucose metabolism, and thus their energy 
production, by limiting their energy metabolism largely to glycolsis, leading to a state 
that has been termed “aerobic glycolysis” [289-290]. 
Glycolytic fueling has been shown to be associated with activated oncogenes 
(e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53), whose alterations in tumor 
cells have been selected primarily for their benefits in cell proliferation, avoidance of 
cytostatic controls, and attenuation of apoptosis [71].  This reliance on glycolysis can be 
further accentuated under the hypoxic conditions that operate within many tumors:  the 
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hypoxia response system acts to up-regulate glucose transporters and multiple enzymes 
of the glycolytic pathway [251].  Thus, both the RAS and hypoxia can independently 
increase the levels of the HIF1α and HIF2α transcription factors, which in turn up-
regulate glycolysis [252]. 
Altered energy metabolism is proving to be as widespread in cancer cells as many 
of the other cancer-associated traits that have been accepted as hallmarks of cancer.  This 
realization raises the question of whether deregulating cellular ene gy metabolism is 
therefore a core hallmark capability of cancer cells that is s fundamental as the six well-
established core hallmarks [127]. 
Another emerging hallmark:  evading immune destruction 
A second, still-unresolved issue surrounding tumor formation involves the role 
that the immune system plays in resisting or eradicating formation and progression of 
tumors, late-stage tumors, and micrometastases [126]. 
The role of defective immunological monitoring of tumors is validate by the 
increases of certain cancers in immunocompromised individuals [281].  An increasing 
body of evidence suggests that the immune system operates as a ignificant barrier to 
tumor formation and progression. 
When immunedeficient mice were assessed for the development of carcinogen-
induced tumors, it was observed that tumors arose more frequently and/orgrew more 
rapidly in the immunodeficient mice relative to immunocompetent controls [270].  In 
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addition, transplantation experiments have shown that cancer cells that originally arose in 
immunodeficient mice are often inefficient at initiating secondary tumors in syngeneic 
immunocompetent hosts, whereas cancer cells from tumors arising in immunocompetent 
mice are equally efficient at initiating transplanted tumors in both types of hosts [160].  
Clinical epidemiology also supports the existence of anti-tumoral immune responses in 
some forms of human cancer [33, 93].  For example, patients with colon and ov rian 
tumors that are heavily infiltrated with CTLs and NK cells have  better prognosis than 
those that lack such abundant killer lymphocytes [212]. 
On the other hand, highly immunogenic cancer cells may well evade immune 
destruction by disabling components of the immune system.  For example, cancer cells 
may paralyze infiltrating CTLs and NK cells, by secreting TGF-β or other 
immunosuppressive factors [308].  More subtle mechanisms operate through the 
recruitment of inflammatory cells that are actively immunosuppressiv , including 
regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs).  Both can 
suppress the actions of cytotoxic lymphocytes [203]. 
Breast Cancer 
Breast cancer (malignant breast neoplasm) is a type of cancer originating from 
breast tissue, most commonly from the inner lining of milk ducts or the lobules that 
supply the ducts with milk [244].  In developed countries, breast cancer is the most 
commonly diagnosed malignancy in women and is the second leading cause of cancer 
death.  Worldwide, breast cancer comprises 22.9% of all cancers (excluding non-
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melanoma skin cancers) in women.  In 2006, estimated new breast cancers in the United 
States were 212,920 and deaths, 40,600 [116].  In 2008, breast cancer caused 458,503 
deaths worldwide (13.7% of cancer deaths in women) [144].  Many women with breast 
cancer do not have any of the known risk factors [116].  The relative risk factors for 
breast cancer include female sex [111], age, lack of childbearing o  breastfeeding, higher 
hormone levels race, economic status and dietary iodine deficiency [303]. Breast cancer, 
like other cancers, occurs because of an interaction between the environment and 
defective gene, such as p53, BRCA1 and BRCA2.  These mutations in breast cancer allow 
uncontrolled cell division, lack of attachment, and metastasis to distant organs [81]. 
Most breast cancers are derived from the epithelium lining the ducts or lobules.  
The in situ carcinomas of the breast are classified as ductal (DCIS), lobular (LCIS), or 
Paget’s disease of the nipple [116].  They are growth of low grade cncerous or 
precancerous cells within a particular tissue compartment such as t e mammary duct 
without invasion of the surrounding tissue.  However, most invasive breast cancers are 
adenocarcinomas, with invasive ductal carcinoma being the commonest (80%) and 
invasive lobular carcinoma occurring approximately 10% of the time [116].  
Several important receptors are expressed on the surface of breast cancer cells, in 
their cytoplasm and in the nucleus.  Hormones bind to receptors and initiate 
transcriptional changes in the cells.  Clinicians often check three critical receptors: 
estrogen receptor (ER), progesterone receptor (PR), and HER2/Neu.  ERs are expressed 
in 60% of all breast cancers and indicate that cancer cells depend on estrogen for their 
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growth, so they can be responsive to ER modulator (e.g. tamoxifen).  This type of cancers 
generally has a better prognosis [197].  HER2-positive breast cancer have a worse 
prognosis, but can respond to drugs such as the monoclonal antibody trastuzumab (in 
combination with conventional chemotherapy), and this has improved the prognosis 
significantly [262].  Cells with none of these receptors are called basal-like or triple 
negative. 
In addition to surgery and radiation therapy, there are currently three main groups 
of medications used for breast cancer treatment:  hormonal manipulation, chemotherapy, 
and monoclonal antibodies.  ER-positive cancers can be treated with ER antagonist, e.g. 
tamoxifen (Nolvadex), or alternatively aromatase inhibitor, e.g. anastrozole (Arimidex) 
or letrozole (Femara).  Chemotherapy is predominately used for stage 2-4 disease, being 
particularly beneficial in ER-negative breast cancer.  Anthracyclines and taxanes are the 
two most active drug classes against breast cancer.  Many patients have often received 
these agents in the adjuvant setting.  Capecitabine is used when the disease has recurred 
or progressed after anthracyclines and taxanes.  The other active drugs include cytoxan, 
methotrexate, vinorelbine, gemcitabine, oral etoposide, and irinotecan. Trastuzumab 
(Herceptin), a monoclonal antibody to HER2, has improved the 5 year disease free 





Tumor Microenvironment and 3D Structure 
Tumor microenvironment is initially recognized in chronic inflammatory state.  
Many cancers will develop as a result of a chronic inflammatory state due to infections 
[171].  This is commonly seen with Hepatitis B and C, which can be a harbinger for 
hepatocellular carcinoma [171].  Gastric infection from Helicobacter pylori, will increase 
gastric cancer risk by 75%, and is the second most common type of cancer globally 
[171].  A few other clinical examples illustrating the association of chronic inflammation 
and increased cancer risk include: inflammatory bowel disease (ulc rative colitis, 
Crohn’s disease) and colon cancer; cervical infection (human papillomavirus) and 
cervical cancer, and chronic reflux esophagitis resulting in Barrett’s esophagus that is 
high risk for esophageal carcinoma [61].  In all cases, these chroni  inflammatory 
conditions help to establish a tumor microenvironment full of deranged proliferative 
signaling networks, which is largely orchestrated by inflammatory cells and is an 
indispensable participant in the neoplastic process [61]. 
Several types of stromal cells such as cancer-associated fibroblasts (CAFs), 
endothelial cells, inflammatory cells, and extracellular matrix (ECM) collectively create 
the microenvironment for epithelial cells [32].  It is the niche of developing cross talk 
between different cells types.  Critical stromal elements such as CAFs provide an 
essential communication network via secretion of growth factors and chemokines, 
inducing ECM alteration to generate additional carcinogenic signals enhancing cancer 
cell proliferation [152].  In cancer invasion, tumor cells secrete a variety of proteins that 
include growth factors and ECM-degrading proteinases to degrade the matrix and its 
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component adhesion molecules.  The matrix degradation takes place in a r gion close to 
the tumor cell surface, where the amount of the active degradative enzymes outbalances 
the natural proteinase inhibitors present in the matrix or that secreted by normal cells 
[128].  Proteins secreted by tumor cell into the ECM microenvironment are therefore 
involved in cell adhesion, motility, intercellular communication and invasion [128].  
Also, the stromal cells induce the requisite transcription programs allowing the necessary 
mesenchymal phenotypes to invade distant tissues and establish a new environment.  The 
cancer cells then shut down the transcription factor programs and reconvert from 
mesenchymal to epithelial cells, thus recreating themselves from the core of primary 
tumor cells [291].  
Fibroblasts 
Fibroblasts were first described in the late 19th century, based on their location 
and their microscopic appearance.  As a member in connective-tissu  family, they are 
dispersed in connective tissue throughout the body, where they secrete a non-rigid ECM 
[201]. 
The primary function of fibroblasts is wound healing.  When a tissue is injured, 
the fibroblasts nearby proliferate, migrate into the wound, and generate ECM to serve as 
a scaffold for other cells, which helps to isolate and repair the damaged tissue [6].  
Fibroblasts synthesize many of the constituents of the fibrillar ECM such as type I, type 
III and type V collagen, and fibronectin [238, 275].  They also contribute to the formati n 
of basement membranes by secreting type IV collagen and laminin [48].  As the principal 
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source of ECM constituents, fibroblasts are considered the main mediators of scar 
formation and tissue fibrosis.  
Additionally, fibroblasts are important in maintaining the homeostasis of adjacent 
epithelia through the secretion of growth factors and direct mesenchymal–epithelial cell 
interactions [296].  The latter may lead to epithelial-mesenchymal transition (EMT), a 
crucial stage involved in cancer cell metastasis.  Fibroblasts are also an important source 
of ECM-degrading proteases such as matrix metalloproteinases (MMPs), which 
highlights their crucial role in maintaining an ECM homeostasis by regulating ECM 
turnover [48]. 
Fibroblasts need to be activated in wound healing.  Inactive fibroblasts, which are 
also called fibrocytes, are smaller and spindle shaped.  They have a reduced rough 
endoplasmic reticulum.  On the other hand, fibroblasts isolated from the site of a healing 
wound or from fibrotic tissue secrete higher levels of normal ECM constituents and 
proliferate more than their normal counterparts isolated from healthy organs [46, 207].  
Such increased activity is referred to as ‘activation’ [46].  Once the wound is repaired, the 
number of activated fibroblasts decreases significantly and the resting phenotype is 
thought to be restored [275].  It remains unknown whether the activated fibroblasts revert 
to a resting phenotype, or whether they undergo apoptosis followed by the repopulation 




It has been studied since 1970 that fibroblasts within the tumor stroma acquire a 
modified phenotype, similar to fibroblasts associated with wound healing [82].  
Therefore, cancer is frequently compared to a wound that never heals.  This is partially 
due to the perpetually activated fibroblasts at the site of the tumor.  This subpopulation of 
fibroblasts in cancer is called cancer-associated fibroblasts (CAFs), commonly identified 
by their expression of α-smooth-muscle actin [21].  In breast carcinomas, about 80% of 
stromal fibroblasts acquire this activated phenotype [243].  It isbecoming clear that 
CAFs are important promoters of tumor growth and progression [205]. 
Local fibroblasts or fibroblast precursors, stimulated by members of the PDGF or 
TGF-β family, have generally been considered as the major source of CAFs [152].  
Recent studies discovered additional cellular sources of CAFs such a bone marrow-
derived cells, malignant epithelial cells, and endothelial cells [39, 152, 312]. 
CAFs are an established source of classical growth factors known to possess a 
tumor-promoting role, for example EGF; TGF-β or HGF [152].  A pro-metastasis effect 
was demonstrated in experiments where different fibroblasts wereco-injected with 
pancreatic cancer cells [142].  Studies also suggested cancer cells and CAFs express 
complementary metabolic pathways which facilitate CAFs to remov  toxic metabolites 
and to buffer the acidity generated by cancer cells, thereby exerting a metabolic pro-
tumorigenic effect [170].  CAFs reduced cancer cells sensitivity to chemotherapy in co-
cultured or cancer cells grown in fibroblast-conditioned medium [142].  Similar findings 
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have been made in breast cancer models where tamoxifen sensitivity was affected by co-
cultured fibroblasts [202].  VEGF derived from CAFs are important for tumor 
angiogenesis [80].  PDGF-dependent CAFs in a genetic model of cervix cancer also 
produced FGF which significantly contributed to tumor angiogenesis [227].  CXCL12 
produced by breast CAFs contributes to the recruitment of bone marrow-derived 
endothelial precursor cells [218].  Finally, CXCL14, which is consistently up-regulated in 
human prostate CAFs, increased tumor content of macrophages, and also stimulated 
tumor growth [12].  In current therapeutic strategy CAFs-secretd tumorigenic molecules 
and the source of CAFs are the two primary targets.  For instance, targeting stromal 
PDGF receptors in tumors increased tumor drug uptake [226].  In another study, 
inhibition of stromal PDGF receptors induced anti-tumoral effects in models of cervix 
and colorectal cancer [162, 227].  Targeting CXCL14 is another potential therapeutic 
approach for its role in CAFs stimulation [309]. 
3D cellular structure 
The mammary gland, like many glandular organs, is embedded in stroma, which 
includes ECM.  ECM not only provides structural support but also signaling cues via 
transmembrane receptors, directing cytoskeletal and chromatin organizatio  to maintain 
tissue integrity [34].  It was shown that collagen gels, which provide a 3D scaffold, allow 
epithelial cells of various tissues and origins to maintain some of their tissue structure and 
differentiated functions [87]. 
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The behavior of invasive carcinomas (e.g. breast, prostate, colon.) in humans can 
be very varied, in that they can metastasize rapidly in one case or take many years to 
become invasive in another [259].  These observations emphasize the dynamic and 
progressive nature of cancer in humans [159].  Heterologous 3D model system  allow 
cells to grow in a niche with similar nature.  This system rflects the distinct invasive 
behavior of human tumor cells, mimics the tumor–stromal cell interactions of human 
carcinomas and allows for systemic investigation into the multiple unknown regulatory 
feedback mechanisms between tumor and stromal cells in a well-defined 3D environment 
[224]. 
The common strategy to construct a 3D system is to isolate cells in tissue culture 
and then implant them in a 3D matrix scaffold as either single cells or as tissue-like 
aggregates.  3D scaffolds have been generated from purified molecules such as collagen 
I, synthetic biomaterials, and even from native ECM from which living cells were 
previously extracted [304].  There are two mostly used methods.  Epithelial cells can be 
completely embedded within the ECM where cells are grown in a gelled bed in the 
presence of culture medium containing growth factors and hormones that are necessary 
for proliferation and survival.  In the overlay method, the ECM is firt cast to form a 
gelled bed measuring 1 mm in thickness.  Epithelial cells are seeded onto this bed as a 
single-cell suspension in culture media.  Other less used methods include gyratory 
rotation and spinner flask spheroid cultures, microcarrier beads and pre-fabricated 
engineered scaffolds [179]. 
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3D cultures have several important advantages over 2D cultures (Fig. 1.2).  
Cellular heterogeneity: 3D cultures are composed of cells with different phenotypes 
caused by mass transport limitations, such as proliferating, non-proliferating and necrotic 
cells, very similar to the situation within intact human tumors.  It is far more realistic than 
the cellular homogeneity found in monolayer culture [159].  Matrix stiffness: the stiffness 
(compliance) of the ECM regulates multiple cellular functions [78].  Cancer cells sense 
external pressure through bidirectional interaction between cellsand the surrounding 
ECM and respond accordingly.  It has been reported that cell surface integrin receptors 
and the contractile cytoskeleton pull against the ECM to sense the stiffness of the 
microenvironment [109].  Cells respond to different stiffness of matrix by shifting 
distribution of cell surface integrin receptors and the types of cell adhesions and 
cytoskeletal structures formed, altering distribution of cell surface integrin receptors and 
the types of cell adhesions and cytoskeletal structures formed, and enhancing cell 
proliferation to promote neoplasia [62, 221].  That explains that pathologica  processes 
such as fibrosis or microenvironmental alteration within and around developing tumors 
can alter cell behavior due to the change in tissue stiffness and cellular responses [89].  
For example, dense, non-pliable desmoplastic tissue is associated wth some carcinomas 
[221] and sites predisposed for secondary metastases [154].  Cell and tissue polarity is a 
common property in epithelial cells.  These cells have the apical and basal surfaces 
crucial for tissue organization and directional secretion of products.  Their basal surfaces 
rest on thin, flat basement membranes comprised of collagen IV, laminin, and many other 
matrix proteins [304].  In normal breast tissue, epithelial cells are organized i to spherical 
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3D structures surrounding a lumen to function as acini of glands.  While cell polarity is 
preserved by culturing cells on a layer of collagen with other stromal factors, this 
organization is lost when these cells are explanted onto flat 2D tissue culture substrates 
[118].  Metastasis: the mechanisms of cell invasion in cancer have been well analyzed in 
3D model systems.  Local cleavage of the surrounding matrix by transmembrane 




Fig. 1.2 Three dimensional culture of breast cancer cells 
(A) Brightfield images of heterologous tumor–stromal spheroids (containi g 
MCF-7 tumor cell line, human mammary fibroblasts and endothelial cells) (taken at ×75 
and ×150 magnification).  (B) H and E sections of heterologous tumor–stromal spheroids 
(containing MCF-7 tumor cell line, immortalized human mammary fibroblasts and 
endothelial cells)(taken at ×150 and ×300 magnification) [159]. 
 26
type matrix metalloproteinases (MT-MMP) family is required for cell proliferation in 
model tumors and integrin-mediated invasion into collagen gels [134].  Similarly, MT1-
MMP allows the expansion of normal endothelial cells to form new blood vessels and 
promotes the differentiation of pre-adipocytes into white adipocyte tissue.  In addition, 
tumor cell adherence and migration in spheroid cultures can reflect the distinct metastatic 
potential of breast tumor cells [52].  Cell signals: human 3D in vitro epithelial models of 
mammary acini can mimic the increasingly abnormal tissue organization characteristic of 
breast carcinoma progression, where tumor cells suppress normal apoptotic mechanisms 
to invade the lumen [72].  Oncogene HER2 is reported to interact with the Par polarity 
complex components partition protein 6 (Par6) and atypical protein kinase C (aPKC) 
[11].  Inhibition of β1-integrin, EGF receptor, MAPK, PI3K, or Par6 can restore acinar 
architecture to a state closer to normal [11, 187].  Furthermore, analyzing patterns of gene 
expression in 3D in vitro mammary acini may be useful for predicting breast cancer 
outcome [35].  Genetic phenotype: many cells types, present in 3D models, were found to 
assume a near normal cellular architecture and exhibit gene expr ssion profiles that were 
reflective of an authentic differentiated phenotype [264].  3D in vitro culture systems 
have been shown to recapitulate the drug sensitivity patterns of tumr cells in vivo.  3D 
multi-cellular tumor spheroids from the breast cancer cell line, MDA-MB-231, exhibited 
a much lower IC50 to cisplatin when plated in 2D monolayer cultures than as suspended 
spheroids.  Treatment of MDA-MB-231 spheroids, but not MDA-MB-231 monolayers, 
by cisplatin demonstrated up-regulation of TGF-ß mRNA and protein wh ch is highly 
predictive of the patterns of drug response of tumor cells in vivo [217]. 
 27
HER2/Neu 
Human epidermal growth factor receptor 2 (HER2) and the rat homologue, Ne , 
belong to ERBB/HER family named from their homology to the erythroblastoma viral 
gene product, v-erbB.  This receptor tyrosine kinase (RTK) family includes four receptors 
HER1–4 and 13 polypeptide extracellular ligands [54] (see Fig. 1.3).  An important 
defining feature of the HER network is that two members of the family, HER2/Neu and 
HER3, are non-autonomous [54].  HER2 lacks the capacity to interact with a growth-
factor ligand, whereas the kinase activity of HER3 is defectiv  [123, 163].  Both HER2 
and HER3 form heterodimeric complexes with other ERBB receptors that are capable of 
generating potent cellular signals. 
HER2 plays a critical role in human development.  In human fetuses, HER2 has 
been detected in heart, the nervous system, developing bone, muscle, skin, lungs and 
intestinal epithelium [60].  For instance, HER2 and HER4 are expressed in the 
myocardium, the underlying muscular portion of the atrium and the ventricl  [54].  
Signals from neuregulin-1 to the HER2/HER4-expressing myocardium nitiates 
ventricular differentiation.  A study shows HER2-mutant mice are embryonic-lethal as 
the lack of HER2 signaling undermines trabeculation in heart development, and the 
mutant heart is characterized by an irregular beat [180].  Normal breast growth and 
development is another example of HER2 involvement after birth.  The EGF-like ligands 
and neuregulins that bind to this receptor family have been shown to stimulate the lobulo-
alveolar development of the mouse mammary gland in explant cultures and in vivo [76]. 
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The HER family of receptors are located at the cell membrane and share a similar 
structure, comprising a cysteine-rich extracellular growth factor (ligand) binding domain, 
a lipophilic transmembrane segment and an intracellular tyrosine kinase domain with a 
regulatory carboxyl-terminal segment [283].  Ligands activate HER receptors via 
receptor dimerization which results in transphosphorylation in theirintracellular tyrosine 
kinases, providing a dock with numerous intracellular signaling molecules leading to 
activation of downstream second messenger pathways and cross talk with other 
membrane signaling pathways [15, 54].  Although no direct ligand has been id ntified, 
HER2 can be activated via heterodimerization with another family member or 
homodimerization with itself when expressed at very high levels [122].  In fact, HER2 is 
a preferred heterodimeric partner of the other three HER members. HER2-containing 
heterodimers have a higher affinity and broader spectrum of ligands than other 
heterodimeric receptor complexes [122].  Also, HER2-containing heterodimers are 
marked by slow endocytosis and frequent circulation back to the cell surface [17, 181, 
297].  In sum, these features translate to more potent mitogenic signals [228]. 
Amplification of the HER2 gene (generation of more than the normal two gene 
copies) is the most common mechanism leading to increased HER2 protein expression, 
disruption of normal control mechanisms and formation of aggressive tumor cells [140, 
143].  Amongst the most prominent pathways are the PI3K/AKT and the MAPK 
pathway. 
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HER2 induces transformation through PI3K/AKT pathway in cooperation with
HER3 [8, 133].  A study shows HER3 provides HER2 the p85 binding motifs to PI3K 
[231, 248, 260].  This is further supported by tumors from MMTV-neu mice and HER2 
overexpressing human breast tumor have activation of PI3K signaling [9, 274, 315].  The 
activation of PI3K/AKT regulates numerous cellular functions in cancer cells including 
cell proliferation and survival, cell size and response to nutrient availability, glucose 
metabolism, epithelial-mesenchymal transition and cell invasiveness, genome stability, 
and angiogenesis [191, 220, 271, 284]. 
The transforming functions of HER2 could also be mediated through Src kinase. 
Evidences suggest there is an association between Src activation nd HER2 
overexpression in MMTV-neu transgenic mice and HER2-positive breast carcinomas 
[295].  It has been reported that HER2 activates Src through increasing its expression and 
stability, or by directly phosphorylating Src on Tyr215 in its SH2 domain [269, 280].  
Given that Src regulates focal adhesions and integrin signaling, and regulation of the 
actin cytoskeleton, this activation in Src will result in an up-regulation in cell migration, 
invasion, and metastasis [295].  In addition, as a downstream signal, Src may play a role 
in upstream activation.  One study indicated c-Src enhances HER2-H3 dimerization 
and increases their phosphorylation and signaling activities [146].  c-Src also 
phosphorylates HER2 at Tyr877 within the activation loop of the kinase domain and 
increases the kinase activity of HER2 [301]. 
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HER2 signaling can disrupt cell polarity and cell adhesion. HER2 receptors are 
normally expressed on the basolateral surface of epithelial cells where it likely mediates 
cross talk with ligand secreting stromal cells [37, 69, 254].  The activation of HER2 leads 
to disruption of tight junctions, loss of cell polarity, and proliferative disarray in breast 
epithelial cell acinar structures [208].  This is partially mediated through its interaction 
with components of the Par polarity complex including PAR6 and aPKC [11].  On the 
other hand, the heterodimerization of HER2 with HER1 promotes the invasive phenotype 
mediated through pathways including PI3K, RAS, PLCγ, STAT3, PKC-α, FAK [23, 145, 
313].  A few important studies reported that HER2 physically interac s with β4 integrin 
[90] and mammary tumors in MMTV-neu mice have delayed onset and reduced invasion 
and metastases if β4 integrin signaling is disrupted genetically [121]. 
HER2-positive breast cancer 
The HER2 gene is amplified in approximately 20 to 30% of breast cancers 
patients.  Breast cancers can have up to 25–50 copies of the HER2 gene, and up to 40–
100 fold increase in HER2 protein resulting in 2 million receptors expressed at the tumor 
cell surface [151].  Half of HER2-positive breast cancers are ER-positive but they 
generally have lower ER levels, and many have p53 alterations [277].  HER2-positive 
breast cancer is associated with aggressive tumor behavior characterized by significantly 
shorter overall survival rate and time to relapse [143]. 
Two drugs are currently FDA approved for treatment of HER2 positive cancers. 
Trastuzumab is a humanized monoclonal antibody that recognizes the external domain of 
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HER2.  HER2-positive breast cancer patients respond well to sole trastuzumab treatment 
[285].  Also, trastuzumab has a synergistic effect when combined with a variety of 
chemotherapy drugs.  For instance, in clinical trials, trastuzumab increased the objective 
response rate and time to breast tumor progression when combined with doxorubicin, 
cyclophosphamide, or paclitaxel [138].  In addition, trastuzumab is beneficial when 
combined with endocrine therapy in both ER and HER2 positive patients [156].  
Lapatinib is a small molecule tyrosine kinase inhibitor that blocks the kinase activity of 
HER1 and HER2 [204].  It is commonly used as a treatment in ER+/EGFR+/HER2+ 
breast cancer patients (now often called "triple positive") and in patients who have 
HER2-positive advanced breast cancer that has progressed after previous treatment with 
other chemotherapeutic agents, such as anthracycline, taxane-derived drugs, or 
trastuzumab.  A 2006 GSK-supported randomized clinical trial on female breast cancer 
patients previously being treated with those agents (anthracycline, a taxane and 
trastuzumab) demonstrated that administrating lapatinib in combination with capecitabine 
delayed the time of further cancer growth compared to a regime that uses capecitabine 
alone.  The study also reported that risk of disease progression was reduced by 51%, and 
that the combination therapy was not associated with increases in toxic side effects [108].  
The outcome of this study resulted in a somewhat complex and rather specific initial 
indication for lapatinib—use only in combination with capecitabine for HER2-positive 
breast cancer in women whose cancer have progressed following previous chemotherapy 
with anthracycline, taxanes and trastuzumab. 
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The synergistic effect of lapatinib with trastuzumab is well documented.  While 
trastuzumab fails to bind to the p95 truncated variant of HER2 (p95 HER2), lapatinib 
remains strong affinity to p95 HER2 and inhibits cell proliferation n trastuzumab-
resistant cells expressing p95 HER2 [245].  It may also circumvent trastuzumab 
resistance associated with up-regulation of IGF-1R signaling [102].  In addition, lapatinib 
retains anti-tumor activity in PTEN-null HER2-overexpressing cell lines whereas 
trastuzumab does not [299].  In clinical study, this drug has been shown to cause 
remissions in trastuzumab-resistant patients and it may be more effective when given 
together with trastuzumab [36].  Also, the combination of lapatinib with certain 
chemotherapy drugs in patients with metastatic disease, has shown promising outcomes 
compared to the chemotherapy drug alone [108]. 
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Fig. 1.3 The HER signaling network and HER2-targeted therapy in breast cancer 
The HER network is a network comprised of an input layer of 4 membrane (M) 
tyrosine kinase (TK) receptors (HER1/EGFR-HER4) and multiple ligands [e.g., EGF, 
TGFα, and heregulins (HRG)]; a signal core processing layer involving a series of 
phosphorylation (e.g., activation of the PI3K/AKT, RAS/MEK/MAPK, and STATs 
kinase cascades) that transmit signals from the receptor layer to the output layer to alter 
expression of genes regulating tumor cell proliferation, survival, and other characteristics 
of the malignant phenotype.  HER2 does not have a ligand, but exists in an open 
conformation exposing its dimerization domain; it can be activated by hetrodimerization 
with other ligand-bound HER members or by homodimerization when it is 
overexpressed.  HER3 lacks the TK activity (X).  Trastuzumab is FDA-approved in both 
the metastatic and the adjuvant settings and the dual HER1–HER2 small molecule TK 
inhibitor lapatinib is FDA-approved in metastatic HER2+ breast cancers [122]. 
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Prolactin 
Prolactin is a polypeptide hormone that is synthesized in and secreted from 
specialized cells of the anterior pituitary gland, the lactotrophs.  This hormone was given 
its name based on the fact that an extract of bovine pituitary glnd would cause growth of 
the crop sac and stimulate the elaboration of crop milk in pigeons or promote lactation in 
rabbits.  Based on its genetic, structural, binding and functional properties, PRL belongs 
to the PRL/growth hormone (GH)/placental lactogen (PL) family group I of the helix 
bundle protein hormones [98]. 
The structure of human PRL is similar to growth hormone.  It is an ami o acid 
chain folded by three intra-molecular disulfide bonds between six cysteine residues 
(Cys4-Cys11, Cys58-Cys174, and Cys191-Cys199 in humans) [58].  The sequence homology 
is around 56% between primates and rodents [257].  In rats [59] and mice [167], pituitary 
PRL consists of 197 amino acids, whereas in sheep [184], pigs [183], cattle [287], and 
humans [256] it consists of 199 amino acids with a molecular mass of ∼23,000 Da. 
PRL is a very versatile hormone.  It plays roles in lactation, luteal function, 
reproductive behavior, immune response, osmoregulation, and angiogenesis.  And 
certainly, its cancer-promoting effect will be discussed at the end of this chapter. 
Location 
PRL is found to be produced in various locations in the human body.  A group of 
cells in anterior pituitary gland was first described to synthesize and secret PRL in light 
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microscopy [132].  These heterogeneously shaped cells [68] are sp sely distributed in 
the lateroventral portion of the anterior lobe and are present as a b nd adjacent to the 
intermediate lobe [211].  They are named as lactotrophs.  
PRL was also detected in brain first by Fuxe et al. [101].  PRL immunoreactivity 
was found in the telencephalon in the cerebral cortex, hippocampus, amygdala, septum 
[74], caudate putamen [88], brain stem [75], cerebellum [253], spinal cord [131], choroid 
plexi, and the circumventricular organs [272]. 
Also, female reproductive organs such as placenta, amnion, decidua, and uterus 
have also been proved to produce PRL-like hormones.  Among them are a family of 
placental lactogens found in the rat, mouse [255], hamster, cow [10], pig [95], and human 
[129].  Recent data showed PRL can be produced in the male reproductive organ such as 
prostate gland [107]. 
Lymphocytes are another source of PRL.  Studies indicated immune-competent 
cells from thymus and spleen as well as peripheral lymphocytes contain PRL mRNA and 
release a bioactive PRL that is similar to pituitary PRL [77]. 
In fact, although a large amount of PRL in milk originates from the pituitary 
gland [120], the epithelial cells of the lactating mammary gland [213] are thought to self-
synthesize PRL as well.  PRL mRNA [213] as well as synthesis of immunoreactive PRL 
has been detected by mammary epithelial cells of lactating rats [189].  In addition, the 
mammary gland may also act as a posttranslational processing site for PRL given the fact 
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that the number of PRL variants in both human milk, far exceeds that found in serum 
[86]. 
Regulation 
Pituitary PRL is regulated by dopamine secreted from the midbrain, substantia 
nigra pars compacta, and hypothalamus [98].  In lymphocytes and in decidual ells, PRL 
expression is stimulated by cAMP [107].  Lymphocytes also contain dopamine receptors 
that may be involved in the regulation of lymphocytic PRL production/releas  [73].  
Progesterone up-regulates PRL synthesis in the endometrium but is a potent inhibitor in 
myometrium and breast glandular tissue [316]. 
During pregnancy, high circulating concentrations of estrogen and progesterone 
inhibit the action of PRL on milk production.  Following delivery, reduced estrogen and 
progesterone production allows PRL to induce lactation.  After childbirth, PRL levels fall 
as the internal stimulus is removed.  Sucking by the baby on the nipple then promotes 
further PRL release, maintaining the ability to lactate [98]. 
Prolactin Receptor 
The human PRL receptor (PRLR) belongs to class 1 of the cytokine receptor 
superfamily.  The PRLR gene is located on chromosome 5 and contains at lea t 10 exons 
[18].  The PRLR exists as seven recognized isoforms as an result of transcription starting 
at different promoters or alternative splicing of the transcript [135] (Fig.1.4).  They 
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include the long isoform, intermediate isoform, two short isoforms, ∆S1 isoform, PRLBP 
and TM-LCD among which the first four are of the most important in PRL signaling. 
The long PRLR was the first human PRLR isoform identified with the longest 
sequence and is a classic type I single-pass cell-membrane receptor that consists of an 
extracellular domain (ECD), a transmembrane domain (TMD) and an intracellular 
domain (ICD).  It is a polypeptide of 211 amino acids and is around 85 kDa.  ECD 
contains two type III fibronectin-like domains, termed the S1 and S2 omains.  The S1 
domain contains the majority of ligand contact sites.  The S2 domain has a smaller 
surface area for interacting with ligand but also contains elements responsible for 
interacting with its partner receptor in the ligand-dimerized complex.  These structures 
contribute to the high affinity of the PRLR for PRL.  The ICD contains Box 1, Variable 
Box (V-Box), Box 2, and Extended Box 2 (X-Box) motifs.  The Box 1 motif provides 
docking site for Janus kinase 2 (JAK2).  The function of the C-terminal region of the ICD 
is thought to bind to the signal transducer and activator of transcription 5 (STAT5) and 
SH2-containing protein tyrosine phosphatase (SHP-2) [7]. 
The intermediate PRLR isoform (50kDa) is truncated in its C-terminus.  This 
results in a deletion of all coding sequence from C terminal to the X-Box.  This isoform 
still engages JAKs but is incapable to activate Fyn tyrosine kinase.  The intermediate 
isoform was unable to trigger the proliferation of transfected cells in response to ligand 
[164]. 
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The S1a (56 kDa) isoform contains both the Box 1 and 2 motifs, whereas the S1b 
(42kDa) PRLR contains only the Box 1 element.  Both short isoforms appear inert from a 
signaling perspective and may serve as ligand traps that function to either internalize 
ligand and/or down-regulate PRL-induced signaling [98]. 
∆S1 (70kDa) isoform is missing the entire S1 domain.  The affinity of the ∆S1 
homodimer for ligand is reduced by approximately 7-fold.  Interestingly, the dose-
dependent activation of associated signaling cascades after ligand stimulation is only 
modestly delayed [165]. 
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Fig. 1.4 Schema of the seven known human prolactin receptor (PRLR) isoforms 
Extracellular and intracellular domains are indicated by ‘ECD’ and ‘ICD’, 
respectively, and the single transmembrane domain is represented by the small circle 
within the membrane.  Designations within the ICD represent the known tyrosine 
residues in the PRLR, and the colored boxes represent the Box 1, V-Box, Box 2 and X-
box (left to right) [56]. 
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Prolactin in Breast Cancer 
Epidemiology 
Hankinson et al. conducted a large prospective nested case-control study of 
plasma PRL levels with premenopausal breast cancer risk (n=235 cases).  They observed 
a significant positive association, with a RR comparing the top versus bottom quartiles of 
PRL levels of 1.5 (95% CI=1.0–2.5) [279].  This association was strongest for ER+/PR+ 
tumors (RR=1.9, 95% CI=1.0–3.7) and for women over age 45 years (RR=2.3, 95% 
CI=1.1–5.0).  In the other two large studies of premenopausal and postmen pausal 
women, PRL tended to be strongly associated with risk of breast cancer mong women 
who were diagnosed within 4 years of their blood collection.  However, in 
postmenopausal women, a statistically significant positive association between PRL and 
breast cancer risk was still observed among cases diagnosed 4–10 years after blood 
collection [279]. 
Other studies have reported that positive staining for PRL in about 80% of 
malignant breast tumors [31].  Increased PRL positivity was significantly associated with 
increased tumor size, higher stage, nodal involvement, and a worse overall survival [30].  
In addition, high pretreatment PRL concentrations have been associated w th treatment 
failure for both tamoxifen and aromatase inhibitors in most studies [16, 29].  Finally, 
prolactinomas, a condition characterized by extremely high PRL levels, may be 
associated with breast cancer development. 
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Prolactin and tumorigenesis 
In breast cancer, PRL prevents apoptosis [176], enhances tumor cell proliferati n, 
promotes angiogenesis, and increases cell motility and metastasis [115, 186, 194, 247].  
PRL mediates its effects via PRLR activating the JAK2–STAT5 [267], RAS-RAF-
MAPK, and PI3K-AKT pathways [4]. 
Both endocrine and autocrine/paracrine sources for PRL exist in mammals.  In the 
1980s, several clinical trials were conducted on breast cancer patients with 
pharmacological agents that inhibited the pituitary secretion of PRL aiming to inhibit 
tumor growth induced by PRL.  The failure led to more thorough investigation in the 
extrapituitary source of PRL [55].  More and more evidences support the fact that the 
synthesis of PRL can locally occur in breast epithelial cells.  A study indicated that 
hypophysectomized breast cancer patients had near-normal PRL levels [172], whereas 
immunohistochemistry studies revealed the expression of immunoreactive PRL protein in 
human breast epithelium [213].  Others suggest that the mRNA for PRL could be found 
in normal and neoplastic human breast epithelium and mammary epithelium from 
pregnant rodents [94].  In fact, 98% of human breast cancers synthesize PRL mRNA as 
detected by in situ hybridization [237].  Other than mammary gland, PRL was also found 
locally expressed in uterus and immune system [55].  Incubation of my metrial or 
leiomyoma cells with anti-PRL antibodies causes a significant decrease in cell number, 
supporting a role for PRL as a paracrine/autocrine growth factor [214].  PRL has also 
been detected in preterm cervical mucus [215] and in about 50% of uterine cervical 
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carcinomas [192].  A B-lymphoblastoid cell line, IM-9-P, produces relativ ly high levels 
of PRL [105].  A myeloid leukemic cell line and myeloblasts from patients with acute 
leukemia produce PRL [168], as do several non-Hodgkin's lymphoma cell lines [193]. 
While PRL significantly contributes to tumorigenesis, PRLR plays  crucial role 
as well.  The studies examining PRLR expression at the mRNA level have suggested an 
association with either ER/PR expression [219] or neoplasia [198].  The expression of the 
PRLR occurred in 80% of human breast cancers, generally in associ tion with the 
expression of estrogen receptor/progesterone receptor (ER/PR) [198]. 
PRL activates a member of the JAK family, primarily JAK2, upon PRLR 
dimerization.  This provides docking sites for proteins with SH2 domains, including 
STATs. As previously discussed, the interaction of JAK2 with the PRLR appears to be 
mediated by an interaction of the membrane-proximal Box 1/Box 2 motif of the PRLR  
with the N-terminus of JAK2 [96, 178].  Loss of JAK2 activity result in ablation of 
PRL-induced STAT5 phosphorylation and downstream gene expression [40].  JAK2 
activity is necessary for the in vitro [300] and in vivo [241] growth and differentiation of 
mammary cells and tissues. 
STAT5 is the downstream signal activated by JAK2.  In commonly studied 
mammary tumor cell lines, including T-47D, MCF-7, and BT-20, PRL treatm nt results 
in increased tyrosine phosphorylation of STATs 1, 3, and 5 [66, 190].  Several studies 
have demonstrated increased levels of STATs 1 and 3 in primary mammary tumors [38], 
and the incidence of elevated STAT5 activation in other tumor types [38] suggests a high 
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probability that these STATs may be elevated in mammary tumors as well.  Kazansky 
and Rosen have demonstrated that STAT5b, but not STAT5a, is a potent mediator of Src-
induced tumorigenesis [157].  STATs are altered by multiple hormones, growth factors, 
and signaling cascades, pointing to an obvious role they may play in cross talk with many 
other agents important in mammary carcinogenesis.  Activation of the STAT complex 
engages its DNA binding sequence, resulting in promoter transactivation under 
appropriate conditions [188]. 
A second pathway that has received focused attention in mammary tumor cells is 
the RAS-RAF-MAPK pathway.  PRL has been shown to activate this pathway in a 
number of PRL-dependent models and mammary tumor cell lines, as well as normal 
mouse mammary epithelial cells [57].  In T-47D cells, this was associated with increased 
association of SHC with JAK2, as well as GRB2 and SOS, indicating  role for JAK2 in 
this cascade.  The p42/44 MAPKs are linked to proliferation for many growth factors in 
many systems and also appear to be linked to PRL-induced proliferation of mammary 
tumor cells [64-65].  In PRL-deficient MCF-7 cells, a MEK1 inhibitor decreased 
proliferation of unstimulated cells.  EGF, but not PRL, was able to overc me this 
inhibition, indicating a critical role for this pathway in PRL, but not EGF-stimulated 
proliferation [247].  PRL also can synergistically activate this pathway, via cross talk 
with other growth factors, depending on the phenotype of the tumor cell.  PRL-induced 
activation of JAK2 resulted in tyrosine phosphorylation of HER2, thereby increasing 
association with GRB2, and activating the RAS-MAPK pathway [306].  p42/44 MAPKs 
are believed to exert these effects on proliferation via multiple mechanisms, including 
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phosphorylation of Ets transcription factors, increasing synthesis of the fos gene family 
(c-fos, Fra-1,2, c-jun, JunB), phosphorylation of carbamoyl phosphate synthetase II, 
leading to increased DNA synthesis, as well as many other protein kinases and other 
substrates in the cytoplasm, indirectly modulating downstream activity [55]. 
PI3K is another pathway involved in PRLR activation.  p85, the regulatory 
subunit of PI3K becomes associated with the PRLR after ligand exposure in transfected 
human embryonic kidney 293 and Chinese hamster ovary cells [25, 305].  PRLR
association with Src family members contributed to PI3K activation in Nb2 cells [5].  
PI3K could potentially be activated by PRL through multiple additional pathways.  It can 
be a target of RAS [239], and the p85 regulatory subunit has been shown to associate 
with several downstream effectors and adaptors of cytokine and growth factor receptors, 
including STAT5, STAT3, IRS 1, Gab1 and Gab 2, and SHP-2 [225, 242], all of which 
have been shown to be activated by PRL, or are associated with the activated PRLR in 
some way .  PI3K-generated phosphoinositides provide docking sites for AKT (protein 
kinase B), which activate AKT by threonine/serine phosphorylation.  This pathway 
initiates survival, inhibits pro-apoptotic signals [153, 169], and also modulates regulators 
of cell cycle progression such as E2-F, and cyclin D1 [110, 206].  Indeed, expression of 
activated AKT retarded mammary involution and contributed to mammary tumor 




Prolactin Receptor Cross Talk 
Mammary development requires coordinated interactions of multiple growth 
factors and hormones. As mentioned earlier, the downstream signaling p thways of 
PRLR are shared by many of these factors and represent potential sites for cross talk, as 
well as putative sites for therapeutic intervention [44].  
Accumulating evidence points to synergistic interactions between PRL and 
estrogen, members of the EGF family, and IGFs.  These factors are the targets of 
endocrine and molecular therapies, and continue to be the focus of pharmaceutical 
development.  However, acquired resistance to existing therapies fter the initial patient 
response has proven a major obstacle in clinical oncology [44].  With the abundance of 
evidence implicating PRL in the cross talk with these proliferative factors in breast 
cancer, PRL and/or PRLR become promising targets. 
PRL cross talk with HER2 and EGFR 
A number of effects of phosphorylation dependent cross talk have been noted for 
PRL and EGF.  Some of these effects may depend on the cellular context (normal vs. 
malignant) in which the cross talk occurs.  Sheffield and colleagues conducted an elegant 
series of studies using the normal murine mammary epithelial clls (NMuMG) model 
system to examine the effects of PRL on EGFR function [91-92, 149, 234].  In those 
studies, PRL caused activation of PKC, but only modest MAPK activation and PRL 
treatment resulted in EGFR threonine phosphorylation.  This PRL-induced EGFR 
phosphorylation was inhibited by a specific PKC inhibitor.  In the NMuMG cells, PRL 
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decreased both basal and EGF-induced EGFR tyrosine kinase activity.  Notably, this 
PRL-induced desensitization of the EGFR was reversed by in vitro dephosphorylation of 
the isolated receptor by treatment with alkaline phosphatase, suggesting it was accounted 
for by the increased threonine phosphorylation.  Furthermore, PRL co-treatment 
dramatically inhibited EGF-induced RAS/MAPK signaling and EGF-induced 
mitogenesis.  Thus, in NMuMG cells, PRL supressed EGFR function by causing PKC-
dependent threonine phosphorylation of EGFR.  In contrast to this inhibitory effect of 
PRL on EGF signaling in normal mammary epithelial cells, other authors studying 
human mammary carcinoma cells have observed crosstalk between PRL and EGF with 
regard to cell migration and gene activation [56, 130, 194].  For example, the Clevenger 
laboratory demonstrated that several human breast cancer cell lines including T-47D, 
MCF-7 and MDA-MB-231 exhibited synergistically increased motility when treated with 
the combination of PRL and EGF compared to the responses to each individual factor 
[194].  This differential response in normal vs. cancerous mammary cells suggests 
potentially important context-specific elements of cross talk betwe n these two factors.  
Frank et al. examined further PRL-EGF cross talk and the effects of PRLon EGFR and 
HER2 in T-47D cancer cells [136].  They found that both PRL and EGF caused robust 
signaling in T-47D cells.  PRL activated JAK2, STAT5, and MAPK, while EGF caused 
EGFR activation and consequent SHC/MAPK activation.  PRL caused phosphorylation 
of both EGFR and HER2 detected by MAPK inhibitors, revealing that this PRL-induced 
phosphorylation was dependent on the MAPK pathway, but not the PKC pathway.  The 
addition of PRL to EGF treatment significantly retarded EGF-induce  EGFR down-
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regulation in an MAPK activation dependent manner and with a time course that 
correlated with the synergistic effects of PRL on EGF signal ng.  These data are notable 
in that they indicate that PRL synergistically augments EGF signaling in T-47D breast 
cancer cells at least in part by lessening EGF-induced EGFR down-regulation and that 
this effect requires PRL-induced MAPK activity and threonine phosphorylation of 
EGFR.  Positive cross talk between PRL and TGF-α in murine mammary epithelial cells 
in vivo to MAPK and reduction of tumor latency is also observed in mouse models.  
Cross talk with estrogen 
Studies have shown that the ability of the rat corpus luteum to resp nd to estrogen 
requires PRL, which can stimulate the expression of the ER.  Transc iption of the genes 
encoding both ERα and ERβ is stimulated by PRL through the JAK2–STAT5 pathway 
and STAT5-response elements that are located in each of the Esr promoters.  A single 
nucleotide difference between these two response elements is responsible for the 
observation that either STAT5a or STAT5b can stimulate Esr1 transcription, whereas 
only STAT5b can activate transcription of Esr2.  The tyrosine kinase JAK2 is required 
for PRL activation of Esr1 promoter activity; however, additional pathways are involved 
in PRL-induced STAT5b phosphorylation, nuclear translocation and DNA binding.  In 
addition to the corpus luteum, PRL-induced ER expression might provide a mechanism 
for the responsiveness of other target tissues, such as the decidua and mammary gland, to 
these two hormones [97]. 
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Cross talk with IGF-II 
Insulin-like growth factor (IGF)-II is a required for PRL-induced up-regulation of 
cyclin D1 and proliferation in normal murine mammary epithelial cells in vivo and in 
vitro.  PRL up-regulated transcript levels of both IGF-I and IGF-II.  Moreover, PRL 
increased cyclin D1 in the presence of the IGF-I receptor neutralizing antibody.  On co-
treatment, IGF-I and PRL elicited cooperative phosphorylation of MAPK and AKT, but 
not STAT5.  This interaction extended to increased activation of activating protein-1 
enhancer elements, phosphorylation of glycogen synthase kinase 3β, induction of cyclin 
D1, and ultimately, increased cell number.  It also increased invasive behavior, which 
correlated with elevated matrix metalloproteinase-2 transcript levels.  Together, these 
data indicate that strong cross talk between PRL and IGF-I augments biological processes 
associated with tumor progression, with implications for therapeutic strategies [45]. 
Prolactin Receptor Antagonists 
As described above, data indicate that anti-PRL therapies for breast cancer, solely 
aimed at PRL from the pituitary only, were bound to be unsuccessful.  As a consequence, 
recent investigations have utilized various strategies that seek to block PRL action both at 
the endocrine and autocrine/paracrine levels.  One approach is to develop PRL analogs 




Phosphorylated prolactin as a natural prolactin receptor antagonist 
Under normal physiologic conditions, 30% or less of PRL is post-translationally 
modified via multiple mechanisms including proteolytic cleavage, glycosylation, and 
phosphorylation [257].  The primary amino acid phosphorylated in human PRL is a 
serine residue at position 179 [278].  In studies using the Nb2 proliferation assay, the 
accepted measure of PRL bioactivity, removal of the phosphorylation motif from rat PRL 
increased PRL-induced proliferation, demonstrating phosphorylation may inhibit t e 
activity of this hormone [288].  Further studies demonstrated that smll reductions in the 
levels of phosphorylated PRL (versus unphosphorylated PRL) led to increased overall 
biological activity suggesting that phosphorylated PRL may act as an antagonist to its 
unphosphorylated counterpart in vivo [288]. 
S179D-human PRL is a molecular mimic of phosphorylated PRL 
The mutant peptide S179D-hPRL was first generated 1998 and resulted from the 
replacement of an aspartic acid in place of serine 179.  It was assumed during the design 
of this mutant PRL that the negative charge of an aspartate residue can mimic a 
phosphorylated serine reside [50]. 
The Nb2 bioassay studies suggested that S179D might inhibit proliferation in a 
non-competitive manner as its antagonism could not be completely reversed by excess 
wild-type PRL [50].  Further studies have also revealed that S179D-hPRL can inhibit the 
growth of prostate cancer cell lines both in vitro and in vivo [298, 302]. 
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In breast cancer cells engineered to be PRL deficient, S179D-hPRL was 
demonstrated to act both as a weak agonist and to antagonize unphosphorylated PRL 
activity, although the antagonism was incomplete [246].  These data have led to the 
suggestion that S179D-hPRL may be exerting its actions through an isotype variant of 
PRLR, termed the PRLR-S1b, instead of through the classical long is form of the PRLR 
in prostate cancer cell line [298].  S179D-hPRL, perhaps acting throug  the PRLR-S1b, 
may be involved in inhibition of the PRL-mediated activation of STAT5, while activating 
MAPK [286]. 
G129R 
The antagonist developed in our lab was initially designed based on the 
presumption of data from the crystal structure of the ligand-dimerized growth hormone 
receptor extracellular domain [70, 261]; given the similarities b tween the PRL and GH 
receptors, it was assumed that PRL induced the sequential dimerization of its receptor 
[51]. 
PRL has four α-helical segments that are connected via loops that provide 
flexibility and allow the helices to be bundled in an anti-parallel (up-up-down-down) 
manner.  Two separate asymmetric receptor-binding regions have been identified in these 
hormones, each of which interacts with the equivalent region of a receptor to form a one-
ligand, two-receptor complex.  Due to differences in affinity betwe n the two receptor-
binding sites, binding occurs sequentially with the higher affinity site ( ite 1) interacting 
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with the first receptor before the lower affinity site (site 2) can interact with a second 
receptor [63, 100]. 
Studies of GH, PRL, and placental lactogen (PL) have shown that the third α-
helix is important to their structure and the function of site 2.  In our lab, substitution of a 
Gly residue in this region with a more bulky and charged Arg residu  results in 
antagonist, G129R [51].  Thus, G129R binds a single PRLR but is impeded from binding 
a second receptor and forming active heterotrimeric complexes (se Fig.1.5).  Our data 
reveal at modest concentrations, G129R binds receptors with a one to one stoichiometry, 
sequestering the receptor from functionally productive binding and activation by 
endogenous wild-type hPRL. 
G129R was demonstrated to have an inhibitory effect on cell proliferation; an 
effect that was shown to synergize with the anti-estrogen agent 4-OH-tamoxifen in 
PRLR-positive T-47D breast cancer cells [51].  In addition, G129R was shown to up-
regulate TGF-β1 (apoptotic factor) secretion and down-regulate TGF-α (survival factor) 
secretion in a dose-dependent manner in T-47D cells [235].  Further studies demonstrated 
that G129R activated caspase-3 to induce cell apoptosis [235] and down-regulated Bcl2 
[20].  The pro-apoptotic effect of G129R was confirmed by terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling assay (TUNEL) among four PRLR-positive 
breast cancer cell lines tested [20].  G129R also inhibited the phosphorylation of STAT3, 
AKT and MAPK in vitro [47, 175].  In vivo studies in a murine tumor model showed that 
G129R inhibited T-47D and MCF-7 tumor growth, while PRL stimulated the in vivo 
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growth of the tumors [49].  In addition, transgenic mice expressing G129R under the 
control of the metallothionein promoter revealed a significant decrease in ductal 
branching and lobular bud formation in the mammary gland and interestingly umor 
appearance was significantly delayed in these mice [51, 276].  Although it was 
demonstrated that G129R had significantly antagonized PRL/PRLR-mediated signaling 
cascades [20, 47, 51, 99, 190, 222], residual agonistic activity of these analogs was also 
observed in other cell bioassay systems [26, 99, 113] and in animal models [27, 200]. 
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Fig. 1.5 Modeling the function and structure of prolactin-receptor antagonists 
(A) Model of the interaction between PRL or PRLR antagonists with the PRLR.  
Since PRL is assumed to induce sequential receptor dimerization via interactions 
involving both binding sites (top panel), mutations introduced in binding site 2 of the 
antagonists are believed to prevent functional receptor dimerization (middle panel).  
When the antagonist is added in molar excess, it prevents PRL binding to the receptor, 
resulting in a lack of receptor activation and prevention of PRL actions (bottom panel) 
[114]. 
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∆1-9-G129R and ∆1-14-G129R 
The ∆1-9-G129R and the ∆1-14-G129R [27] contain both the G129R 
replacement and deletion of the N-terminal nine or fourteen amio acids of PRL.  The 
design of these mutants was based in part on crystal structure analysis of the placental 
lactogen/PRLR-ECD crystal structure, which revealed a critical role of the N-terminus of 
PRL in the interaction of site 2 with the PRLR [85].  Allegedly, the partial agonism 
observed with the G129R peptide was abolished in the ∆1-9-G129R and ∆1-14-G129R.  
Significant inhibition of PRL-induced cell proliferation and decreased levels of PRL-
induced STAT5 phosphorylation were observed in ∆1–9-G129R or ∆1-14-G129R treated 
T-47D human breast cancer cells [27]. However, the antagonism was noted only when 
these peptides were used in at least 50-fold excess [27].  At the in vivo level, the ∆1-9-
G129R was also found to block STAT5 activation in probasin-PRL transgenic mice, 
using doses of between 0.25 mg-1 mg/mouse day [27, 112].  In addition, diminished 
MAPK and STAT3/5 activation in PRL-stimulated murine mammary glands was noted 
following co-injection of a 50-fold excess of ∆1-9-G129R [27].  The affinity of the ∆1-9-
G129R and the ∆1-14-G129R for the PRLR remains problematic. 
G129R fusion proteins 
G129R has a short half life in vivo [175].  To extend serum half-life (by 
increasing the molecular mass of the antagonist to inhibit its egress through the 
glomerular filtration apparatus) and add other potential anti-tumor functionalities, fusion 
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peptides between the G129R and potential anti-tumor peptides have been generated that 
include: G129R-IL2, G129R-endostatin, and, G129R-PE40-KDEL. 
Interleukin-2 (IL-2) is a 15 kDa glycoprotein that stimulates he activation and 
proliferation of T lymphocytes and natural killer cells.  Although IL-2 was one of the first 
cytokines used for tumor immune therapy in the generation of lymphocyte-a tivated 
killer (LAK) cells, its profound side effects currently limit its direct in vivo application.  
The G129R-IL-2 fusion protein was designed to treat breast cancer by combining PRL 
endocrine therapy and IL-2 immune therapy in one compound [314].  This fusion protein, 
G129R-IL2, was hypothesized to localize IL-2 in breast cancer tumor sites resulting in 
PRLR antagonism and activation of T lymphocytes for site-specific tumor cytotoxicity.  
When examined in vitro the G129R-IL-2 was demonstrated to inhibit PRL-induced 
STAT5 phosphorylation and breast cancer cell proliferation [314].  Treatm nt of Balb/c 
mice injected with EMT6 transfectants overexpressing PRLR with 100 µg G129R-IL-
2/mouse per day, resulted in a statistically significant reduction in tumor size. 
Endostatin is a recognized inhibitor of endothelial cell proliferation and 
angiogenesis [310], thus the fusion peptide was hypothesized to suppress PRL-induced 
tumor cell functions and reduce tumor-induced angiogenesis.  The G129R-endostatin 
fusion protein was demonstrated to inhibit human umbilical vein endothelial cell 
(HUVEC) proliferation and the formation of endothelial tube structure in vitro.  In vivo, 
nude mice injected with 4T1 cells demonstrated an enhanced half life in serum of the 
G129R-endostatin fusion protein and a statistically significant reduction of tumor volume 
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and mass in comparison to those mice that were treated with 5 mg G129R/kg/day or 
endostatin alone [19]. 
Another fusion peptide examined is the G129R-PE40-KDEL construct.  
Pseudomonas exotoxin A (PE) is a bacterial toxin which inhibits protein synthesis via its 
PE40-KDEL moiety.  This fusion toxin competitively binds to PRLR on T-47D human 
breast cancer cells and inhibits STAT5 phosphorylation induced by hPRL.  In addition, 
G129R-PE40-KDEL is selectively cytotoxic to breast cancer cell lines xpressing the 
PRLR and that cell death is associated with the inhibition of protein synthesis and does 




HYPOTHESIS AND OBJECTIVE 
 
 
Previously, we reported that a PRLR antagonist, G129R, exerts an additive effect 
with humanized anti-HER2 monoclonal antibody, trastuzumab in female MMTV- neu 
transgenic mice [250], i.e. inhibiton of PRLR will enhance the inhibitory effect of 
trastuzumab on HER2. However, the effect of G129R on HER2 was abolished when it 
was used to treat primary tumor cells in 2D monoculture setting.  I believe that the 
discrepancy of G129R’s inhibitory effect on HER2 signaling i  vivo and in tissue culture 
is, at least in part, due to the tumor microenvironment disruption in primary cell culture.  
Therefore, I hypothesize that the stromal-epithelial interactions play an important role in 
modulating the cross talk between PRLR and HER2/Neu in breast cancer.  
 
My main objective in this dissertation study, therefore, is to investigate the 
mechanisms by which the tumor stroma exerts its influence on the cross talk between 
PRLR and HER2 in cancerous epithlium.  Specifically, I plan to compare the response of 
tumor epithelium to G129R between epithelial monoculture and epithelial/stroma cells 
co-culture model. Furthermore, I will attempt to investigate the potential molecular 
mechanisms of epithelia-stroma interaction modulating PRLR and HER2 crosstalk using 
various systems such as coculture, transwell, and matrigel models. Finally, I plan to test 









Breeding pairs of FVB/N-Tg (MMTVneu) 202Mul/J mice, expressing the wild-
type rat neu transgene under the control of the mouse mammary tumor promoter 
(MMTV- neu), were obtained from The Jackson Laboratory (Bar Harbor, ME).  The 
colony was expanded and housed in accordance with The Guide for the Care and Use of 
Laboratory Animals.  All animal studies were reviewed and approved by Clemson 
University Institutional Animal Care and Use Committee. 
Preparation of Tumor Lysates 
Tumors were resected (see Fig.3.1) with a sterile scalpel and w shed in PBS, pH 
7.4.  Tissues were minced into paste with a sterile scalpel before being washed three 
times in PBS.  The paste then was suspended in lysis buffer (50 mM Tris·HCl, pH 7.4; 
1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA, pH 8.0; 1 µg/ml 
aprotinin; 1 µg/ml leupeptin; 1 µg/ml pepstatin A; 170 µg/ml PMSF; 180 µg/ml Na3VO4; 
50 mM NaF) and homogenized using an electric homogenizer (250 mg tumor tissue per 1 
mL lysis buffer).  Lysates were harvested into microcentrifuge tubes, placed on ice for 15 
min and centrifuged at 15,000 ·g for 15 min at 4ºC.  Supernatants were collected and the 
protein content was determined using Coomassie Plus Protein Assay reagent and BSA 
standards (Thermo Scientific, Rockford, IL). 
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Fig. 3.1 Preparation of breast tumors in female MMTV- neu transgenic mice 
Female MMTV-neu transgenic mice were killed with cervical vertebrate 
dislocation method (A).  The breast tumors were identified and located.  The surgical a ea 
was cleaned with 70% ethanol.  (B) The surgical area was shaved and sterilized w th 70% 
ethanol one more time.  Breast tumors were resected by sterile scalpel or sciss s [232]. 
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Preparation of Lung Lysates 
Whole lung tissues were resected with a sterile scalpel and w shed in PBS, pH to 
7.4.  Lungs were carefully examined under dissecting microscope.  Metastatic tumors in 
lungs were carefully resected using a sterile scalpel or scissors and tumors from an 
individual mouse were transferred together into a sterile petri dish.  Lung tissues or 
tumors were minced into paste with a sterile scalpel before being washed three times in 
PBS.  The paste was suspended in lysis buffer and homogenized using an electric
homogenizer (250 mg tumor tissue per 1 mL lysis buffer).  Lysates were harvested into 
microcentrifuge tubes, placed on ice for 15 min and centrifuged at 15,000g for 15 min at 
4ºC.  Supernatants were collected and the protein content was determin d using 
Coomassie Plus Protein Assay reagent. 
Preparation of Mammary Gland Lysates 
Five pairs of mammary glands were identified in the thoracic and abdominal 
region of the mice (see Fig. 3.2).  Complete mammary glands were resected with a sterile 
scalpel and washed in PBS, pH 7.4.  Tissues were minced into paste with a sterile scalpel 
before being washed three times in PBS.  The paste then was suspended in lysis buffer 
and homogenized using an electric homogenizer (250 mg tumor tissue per 1 mL lysis 
buffer).  Lysates were harvested into microcentrifuge tubes, placed on ice for 60 min and 
centrifuged at 15,000 ·g for 10 min at 4ºC.  The fatty layer on the top of the solution and 
the precipitate were removed.  The clear middle layer of the supernatant  
 61
 
Fig.3.2  Preparation of mammary glands in female MMTV- neu transgenic mice 
(A) Scheme reporting the localization of mammary glands (Murphy E.D., chapter 
27 Characteristic Tumors, in E.L. Green Ed., "Biology of the Labor tory Mouse", 
reproduced by permission of McGraw-Hill, New York 1966). (B) A median longitudinal 
cut in mouse was made with a sterile scalpel and the skin was separated from the 
underlying musculature. The skin is then dissected and turned on one side and then on the 
other, so as to obtain an examination field as wide as possible. The characteristics of 
mammary glands and of the skeletal muscles will then be apparent [1]. 
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was collected and the protein content was determined using Coomassie Plu  Protein 
Assay reagent. 
Coomassie Plus Protein Assay 
Six standard solutions (1 mL each) containing 0, 250, 500, 1000, 1500 and 2000 
µg/mL BSA were prepared.  The Coomassie®Plus Reagent was allowed to warm up to 
room temperature (RT).  The Coomassie® Plus Reagent solution was immediately mixed 
before use by gently inverting the bottle several times.  0.05 ml of each standard sample 
was pipetted into appropriately labeled test tubes.  1.5 ml of the Coomassie® Plus 
Reagent was added to each tube and mixed well.  Samples were incubated for 10 minutes 
at room temperature (RT).  With the spectrophotometer set to 595 nm, the instrument was 
calibrated on a cuvette filled only with reagent.  Subsequently, the absorb nce of all the 
samples was recorded.  The average 595 nm reading for the Blank replicates was 
subtracted from the 595 nm readings of all other individual standard and unknown 
sample replicates.  Finally, a standard curve was created by plotting the average Blank-
corrected 595 nm reading for each BSA standard vs. its concentration in µg/ml.  The 
standard curve was used to determine the protein concentration of each unknown sample. 
For test samples, lysates were diluted 10 fold in distilled water before they were 
added into 1.5 ml of the Coomassie® Plus Reagent in each tube.  Tubes were covered 
with parafilm and mixed well by inverting several times.  Samples were subsequently 
incubated for 10 min at room temperature before being read in the spectrophotometer set 
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to 595 nm.  Using the readings, protein concentration of lysates was determined 
according to the standard curve. 
Cell Lines and Reagents 
 MCNeuA epithelial and N202Fb3 CAF clonal cell lines established from a female 
MMTV- neu mouse mammary tumor were kindly provided by Dr. Michael Campbell 
(University of California, San Francisco, CA) [43].  Human SK-BR-3 breast cancer cells 
and CRL-7236 primary human CAFs were obtained from the ATCC (Manassas, VA).  
Two types of primary mouse embryonic fibroblasts (MEFs) were derived from the 
embryos of non-transgenic (NTG-MEFs) and MMTV-neu transgenic (NEU-MEFs) 
FVB/N mice as described previously [209].  All cell lines were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 10 µg/ml gentamicin at 37°C in a 5% CO2 humidified atmosphere.  All cell culture 
reagents were purchased from Invitrogen (Carlsbad, CA).  The recombinant human PRL 
and its antagonist analog, G129R, used for all experiments were prepared in house as 
described previously [250]. 
Preparation of Tumor Chunks and Primary Tumor Cells 
Spontaneous mammary tumors from female MMTV-neu mice were resected, 
rinsed in ice-cold phosphate buffered saline (PBS), and minced into tumor chucks (~3 
mm3) using a sterile scalpel.  A portion of the tumor chunks were minced further, 
incubated in 0.25% trypsin-EDTA (Invitrogen) for 30 min at 37°C with constant mixing, 
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and filtered through a 100-µm cell strainer.  The cell suspension was centrifuged at 800g 
for 10 min and resuspended and incubated in ACK Lysing Buffer (Lonza, Walkersville, 
MD) for 10 min prior to filtration through a 40-µm strainer.  The single cell suspension of 
primary tumor cells were centrifuged at 300g for 10 min, resuspended i  PBS, and the 
cells were counted with a hemocytometer. 
FACs Analysis of Primary Tumor Cells 
 Primary tumor cells (3 x 105 cells) were suspended in 30 µl of rat anti-EpCAM 
(14-5791-81; eBioscience, San Diego, CA) diluted in PBS (1:1000), incubated for 15 min 
on ice, and centrifuged at 500g for 2 min.  This process was repeated using goat anti-rat 
IgG-PE (sc-3740; Santa Cruz Biotechnology, Santa Cruz, CA) diluted in PBS (1:60), 
rabbit anti-PRLR(M170) (sc-30225; Santa Cruz Biotechnology) diluted in PBS (1:30), 
and goat anti-rabbit-IgG-FITC (sc-2012; Santa Cruz Biotechnology) dilute  in PBS 
(1:60).  Finally, the cells were suspended in 400 µl of PBS and the surface expression of 
EpCAM and PRLR were evaluated by flow cytometry with a FACSCalibur instrument 
using CellQuest software (Becton Dickinson, San Jose, CA).  As negativ  controls, 
irrelevant antibodies of the same isotypes (Becton Dickenson) were us d in replacement 
of anti-EpCAM and anti-PRLR.  The fluorescence of PE and FITC was excited with an 
argon laser at 488 nm and detected at 570 nm and 530 nm, respectively. 
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Immunohistochemical and H&E staining 
Tumor chunks were fixed with 10% neutral buffered formalin overnight, paraffin 
embedded, and sections (5 µm) were mounted on slides.  Deparaffinized tissue slides 
were rehydrated, and heat induced epitope retrieval was performed in citrate buffer using 
a pressure cooker (20 min at 80 pKA).  MCNeuA and N202Fb3 cells were mono- or co-
cultured at a ratio of 4:1 on poly-prep slides (Sigma-Aldrich, St. Louis, MO) in DMEM 
supplemented with 10% FBS for 24 hrs at 37°C in a 5% CO2 humidified atmosphere.  
Cells were fixed with 10% neutral buffered formalin for 10 min and permeabilized in 
10% Triton X-100 for 10 min. 
For immunohistochemical staining, endogenous peroxidase activity was blocked 
with 3% H2O2 in PBS for 10 min prior to blocking in horse serum for 30 min.  Slides 
were incubated overnight in horse serum with a 1:2000 dilution of rabbit anti-cleaved 
caspase-3 (9961; Cell Signaling, Beverly, MA), a 1:500 dilution of rabbit anti-Ki-67 
(ab16667; Abcam, Cambridge, MA), a 1:1000 dilution of mouse anti-vimentin (ab7752; 
Abcam), a 1:200 dilution of rabbit anti-E-cadherin (4065; Cell Signaling), or as a 
negative control a 1:200 dilution of mouse or rabbit IgG.  The UltraVision ONE 
Detection System HRP Polymer and DAB Plus Chromogen kit (Thermo Scientific, 
Rockford, IL) was used to detect all antigens.  The slides were counterstained with 
hematoxylin and bluing reagent and mounted with coverslips using Permount ing 
medium (Fisher Scientific). 
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For H&E staining, deparaffinized slides were stained with hematoxylin for 5 min, 
washed with acetalcohol for 30 sec, and then stained with eosin for 2 min (all from 
Sigma).  Slides were imaged with an Olympus microscope and images were obtained 
with a CCD cooled 1.5-megapixel camera. 
Tumor Chunk Culture 
Mammary tumors from female MMTV-neu transgenic mice were resected and 
transferred into a petri dish, rinsed in ice-cold PBS, and minced into tumor chunks (~3 
mm3) using a sterile scalpel.  Tumor chunks were then washed three times in PBS prior to 
being seeded into 12-well tissue culture plates and cultured in 1.5 ml of serum-free 
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA) for 24 hrs at 
37°C in a 5% CO2 humidified atmosphere.  The tumor chunks were treated with PRL or 
G129R for 24 hrs.  Experiments were terminated by washing the tumorchunks with ice-
cold PBS supplemented with 0.4 mM sodium orthovanadate.  The tumor chunks were 
resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% (v/v) NP-40) 
supplemented with protease inhibitors (100 mM sodium fluoride; 2 mM EDTA; 1 mM 
phenylmethylsulfonyl fluoride; 1 mM sodium orthovanadate; 5 µg/ml aprotinin; 5 µg/ml 
leupeptin) at a concentration of 250 mg/mL and homogenized using an electric 
homogenizer.  Lysates were harvested into microcentrifuge tubes, placed on ice for 15 
min and centrifuged at 15,000 ·g for 15 min at 4ºC.  Supernatants were coll cted and the 
protein content was determined using Coomassie Plus Protein Assay reagent. 
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Primary Tumor Cell Culture 
Mammary tumors from female MMTV-neu transgenic mice were resected and 
transferred into a petri dish before they were rinsed in ice-cold phosphate buffered saline 
(PBS).  One portion of the tumor was made into tumor chunks as described above.  The 
second portion of tumor was minced into paste with a sterile scalpel in a petri-dish, 
treated with 0.25% trypsin-EDTA (Invitrogen) at 37°C for 30 min with constant shaking, 
and filtered through a 100-µm cell strainer.  The single cell suspension was centrifuged at 
800g for 10 min and resuspended and incubated in ACK Lysing Buffer (Lonza, 
Walkersville, MD) for 10 min.  The cell suspension was filtered through a 40-µm strainer 
and centrifuged at 300g for 10 min.  The cell pellet was washed with PBS and 
resuspended in DMEM supplemented with 10% fetal bovine serum (FBS; Invitrogen) 
and seeded (1 x 106 cells/well) into 6-well tissue culture plates.  The cells were 
monolayer cultured for 24 hrs at 37°C in a 5% CO2 humidified atmosphere.  The cells 
were treated with PRL or G129R for 24 hrs after the depletion in DMEM supplemented 
with 0.5% CSS for 1 hr at 37°C.  Experiments were terminated by washing the cells with 
PBS supplemented with 0.4 mM sodium orthovanadate and resuspending them in lysis 
buffer supplemented with protease inhibitors.  Cell lysates were havested into 
microcentrifuge tubes, placed on ice for 15 min and centrifuged at 15,000g for 15 min at 
4ºC.  Supernatants were collected and the protein content was determin d using 
Coomassie Plus Protein Assay reagent (Thermo Scientific, Rockford, IL). 
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Co-culture 
For direct co-culture, MCNeuA cells were mixed with various ratios of N202Fb3 
CAFs or with a 4:1 ratio of NTG-MEFs or NEU-MEFs; SK-BR-3 cells were mixed at a 
4:1 ratio with N202Fb3, NTG-MEFs, NEU-MEFs, or human CAFs.  The cells were 
seeded (1 x 106 cells/well) in 6-well tissue culture plates and incubated for 24 hrs.  The 
cells were serum-starved in DMEM supplemented with 0.5% charcoal stripped serum 
(CSS) for 1 hr prior to treatment with G129R or PRL for 1, 6 or 24 hrs.  Experiments 
were terminated by washing the cells with PBS supplemented with 0.4 mM sodium 
orthovanadate and resuspending them in lysis buffer supplemented with protease 
inhibitors.  Cell lysates were scraped off with a cell lifter, harvested into microcentrifuge 
tubes, placed on ice for 15 min and centrifuged at 15,000g for 15 min at 4ºC.  
Supernatants were collected and the protein content was determined using Coomassie 
Plus Protein Assay reagent. 
Transwell Co-culture 
The experiment was carried out in 6-well cell culture plates using transwell inserts 
with 0.4 µm polycarbonate membranes (Corning, Corning, NY) (see fig.8).  8 x 105 
MCNeuA epithelial cells were seeded in the bottom chamber and 2 x 105 N202Fb3 CAFs 
were seeded on the insert.  The cells were incubated in 2.5 ml (per well) of DMEM 
supplemented with 10% FBS at 37°C in a 5% CO2 humidified atmosphere.  After serum 
starved in 2 ml of DMEM supplemented with 0.5% CSS, cells were trated with G129R 
or PRL for 24 hrs.  Experiments were terminated by removing the inserts and washing the 
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cells in the bottom chamber with PBS supplemented with 0.4 mM sodium orthovanadate 
and resuspending them in lysis buffer supplemented with protease inhibitors.  Only the 
epithelial cells in the bottom chamber were scraped off with a cell lifter, harvested into 
microcentrifuge tubes, placed on ice for 15 min and centrifuged at 15,000g for 15 min at 
4ºC.  Supernatants were collected and the protein content was determin d using 
Coomassie Plus Protein Assay reagent. 
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Fig. 3.3 Illustration of transwell culture apparatus 
The bottom of the transwell insert is attached with a piece of 10 µm thick 
translucent polycarbonate membrane.  The membrane is featured with micropores with a 
density of 1x105 per cm2 and a size of 8 µm.  The hanging design keeps the Transwell® 
membrane about a millimeter off the bottom of the well.  This prevents co-cultured cell 
monolayers in the bottom of the well from being scratched or disturbed wh n the insert is 
moved.  Windows or openings in the sides of the Transwell insert allow ccess to the 
lower compartment (see Transwell® manual). 
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Fibroblast Debris Co-culture 
2 x 105/well N202Fb3 CAFs were seeded in 6-well culture plates and incubated in 
DMEM supplemented with 10% FBS at 37°C in a 5% CO2 humidified atmosphere before 
being harvested by scraping cells in PBS.  The cells were homogenized with a Potter-
Elvehjem homogenizer, and centrifuged at 500g for 5 min at 4°C.  Insoluble components 
containing cell membrane debris were collected and mixed with MCNeuA cells at 
various ratios and seeded (8 x 105 MCNeuA cells/well) into 6-well cell culture plates.  
The cells were incubated in 2 ml (per well) of DMEM supplemented with 10% FBS at 
37°C in a 5% CO2 humidified atmosphere.  Experiments were terminated by washing t e 
cells with PBS three times to make sure all the cell debris was removed.  Cells were then 
suspended in lysis buffer supplemented with protease inhibitors.  Cell lysates were 
scraped off with a cell lifter, harvested into microcentrifuge tubes, placed on ice for 15 
min and centrifuged at 15,000g for 15 min at 4ºC.  Supernatants were collected and the 
protein content was determined using Coomassie Plus Protein Assay reagent. 
Preparation of Tissue and Cell Lysate 
 All lysate was prepared in RIPA buffer (50 mM Tris·HCl, pH 7.4; 150 mM NaCl; 
1% NP40; 0.25% Na-deoxycholate; 1 mM EDTA, pH 8.0) supplemented with 1x 
protease and 1x phosphatase inhibitors (78430 and 78428; Thermo Scientific).  Tumor 
chunks were transferred to tubes, weighed, and suspended in lysis buffer at a 
concentration of 250 mg/mL and homogenized with a Polytron homogenizer.  Cells 
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cultured as monolayers in 6-well plates were lysed in 0.2 ml of lysis buffer.  Clarified 
lysate and protein content were prepared as described previously [250]. 
Immunoprecipitation of Prolactin Receptors 
Cells were lysed in 1mL of modified RIPA Buffer to which proteas  inhibitors 
were added.  Cells lysate was collected into microcentrifuge tubes, centrifuged at 18,000g 
for 30 min and the supernatant was subject to immunoprecipitation.  The conc ntrations 
of the clarified cell lysates were determined using the Coomassie Plus Protein Assay 
reagent with BSA standards (Thermo Scientific).  Approximately 1 mg of cell lysate was 
incubated with 5 µg of rabbit anti-PRLR (M170) (sc-30225, Santa Cruz Biotechnology) 
and 25 µl of protein G-sepharose (GE Healthcare Sciences) overnight at 4ºC on a slowly 
rotating wheel.  Immunoprecipitates were washed once in 1 ml of washing buffer (50mM 
HEPES, pH7.5; 150mM NaCl; 5mM EDTA; 50mM Tris-HCl, pH7.5; 0.05% Triton X-
100).  The immunoprecipitate was collected by centrifugation, washed, and resuspended 
in sample buffer (1%SDS; 100mM DTT; 50Mm Tris, pH7.5; 0.05% bromophenol blue).  
Whole cell lysate and immunoprecipitate were resolved by SDS-PAGE and western 
blotted for PRLR as described below.   
SDS-PAGE and Western Blot Analysis 
Tissue or cell lysates (30-60 µg/well) were mixed with Laemmli buffer (4.4 ml 
0.5 M Tris, pH 6.8; 4.4 ml Glycerol; 2.2 ml 20% SDS; 0.5 ml 1% Bromophenol Blue; 0.5 
ml Beta-mercaptoethanol) and heated to 80-100ºC for 5 min prior to being loaded on 4-
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15% gradient polyacrylamide gels (Bio-Rad, Hercules, CA).  The gels w re run at 100 V 
for 2 hrs (or until bromophenol blue dye front reaches the bottom of the gel) in the Bio-
Rad Mini-Gel Box system with running buffer (30.3 g (0.25 M) Tris Base, 144 g (1.92 
M) Glycine, 10 g (1%) SDS, 1000 ml ddH2O Dilute 1:10 with ddH2O. pH will be 8.3).  
The gels then were placed in a transfer sandwich (black side, fiber pad, filter paper, gel, 
nitrocellulose membrane, filter paper, fiber pad, and red side).  Any bubbles were rolled 
out after each layer.  The transfer sandwich was run in the Bio-Rad transblot system at 
4°C using an ice pack with transfer buffer (28.8g glycine, 6.04g Tris base, 100ml 
methanol, 1.6L double distilled water).  Running time was 12 W for 2 hr.  
After the transfer, the membranes (facing up) were blocked with 5% nonfat dry 
milk in TBS-T (960 mL distilled water, 30 mL 5 M NaCl, 10 mL 1 M Tris-HCl, 0.5 mL 
100% Tween 20) pH 7.4 (1g/20 mL) for 1 hr., on the shaker, at room temperature.  The 
blots were then incubated overnight with a 1:1000 dilution of rabbit anti-phospho-Neu 
(sc-12352; Santa Cruz Biotechnology, Santa Cruz, CA), a 1:1000 dilution of rabbit anti-
Neu (sc-284, Santa Cruz Biotechnology), a 1:1000 dilution of rabbit anti-PRLR (sc-
20992, Santa Cruz Biotechnology), a 1:10,000 dilution of mouse anti-β-actin (A1978; 
Sigma-Aldrich), or a 1:1000 dilution of mouse anti-β-tubulin (sc-55529; Santa Cruz 
Biotechnology).  Subsequently, membranes were washed with deionized wat r and TBS-
T respectively before the incubation with secondary incubation using either a 1:2,000 
dilution of horseradish peroxidase conjugated goat anti-rabbit IgG or goat anti-mouse 
IgG (Bio-Rad).  Western blot detection was carried out using ECL detection reagent (GE 
Healthcare Sciences, Piscataway, NJ) with blots being incubated in ECL solution for 1 
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min.  Blots were imaged for 10 min and analyzed with the FluorChem Q I aging System 
and AlphaView Q software (Cell Biosciences, Santa Clara, CA). 
Biopsy and Treatment of Spontaneous Mammary Tumors in Female MMTV-neu 
mice 
Tumor-bearing MMTV-neu female mice were anesthetized.  Following 
anesthetization, a small incision was made next to the tumor and a piece (~0.05-0.2 g) of 
tumor was excised and frozen on dry ice.  The incision was closed with 9 mm autoclips 
(Clay Adams-Becton Dickinson and Company, Sparks, MD) and the mice were allowed 
to recover from surgery for 48 hrs.  The mice were treated with Vehicle or G129R for 
various intervals of time.  Approximately 24 hrs after the final i jection, mice were 
euthanized and tumors were resected and frozen on dry ice.  Pre- and post-treatment 
biopsies were lysed and blotted as described above. 
3D Culture 
Matrigel was thawed out at 4°C overnight.  20 ml matrigel was used to coat the 
prechilled 12-well plates to form a thin layer at the bottom.  Plates were incubated for 
15–30 min at 37°C to allow the gel to solidify (but do not let it overdry).  Cells (1 x 
105cells/well) were trypsinized from a monolayer to a single-cell suspension and pelleted 
by centrifugation at 115g before resuspended in the mixture of DMEM (500ul/well) and 
matrigel (120 µl/well).  The mixture of cells was placed onto the coated surface and was 
allowed to settle and attach to the matrigel at the bottom for 30 min at 37ºC.  Another 500 
 75
µl DMEM and 120 µl EHS were added on top of the gel and the culture was maintained 
for 4 days before treatments were carried out (see Fig. 3.4). 
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Fig. 3.4 Illustration of three-dimensional cell culture in matrigel 
(A) In the overlay method, the ECM is first cast to form a gelled bed measuring 1 
mm in thickness.  Epithelial cells are seeded onto this bed as a single-cell suspension in 
culture media.  (B) Microscopic image of tumor cells forming spheres in matrigel [72]. 
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Statistical Data Analyses 
For immunoblots, the Blots were imaged and analyzed with the FluorChem Q 
Imaging System and AlphaView Q software (Cell Biosciences, Santa Clara, CA).  
Densitometric values of the net intensity were based on replicates of quantified protein 
bands normalized to the β-actin or β-tubulin levels and the results were expressed as the 
percentage change of the mean ± SD.  Statistical differences between the groups were 
determined using Student’s t-test and a two-tailed distribution with unequal variances.  A 






Neu Activation Level is Not Related to Tumor Size or Tumor Onset in Female 
MMTV-neu Transgenic Mice 
As tumor size and tumor onset differ among individual mice, the p-Neu status was 
investigated in mammary tumors, normal mammary glands, metastatic lungs and normal 
lung tissues in MMTV-neu transgenic mice.  In the first group, 10 mice of the same age 
with mammary tumors of different sizes were selected.  Tumors were resected and 
weighed.  Healthy and tumor harboring lung tissue were also remved and made into 
lysates.  No correlation was detected between tumor size and p-Neu lev l (only 
representative data are shown).  Also, p-Neu levels in metastatic lung tumors did not 
appear to be consistent with that in original mammary tumors.  Neu was minimally 
expressed and no activation was observed in healthy lung tissues (Fig. 4.1).  In the second 
group, 10 mice with the same tumor onset were selected.  Normal mammary glands along 
with mammary tumors in various sizes were resected from female MMTV-neu mice.  No 
correlation was observed between latency and p-Neu level (Only representative data are 
shown).  No Neu activation was detected in mammary glands.  The third group was 
comprised of eight female MMTV-neu mice with tumors in about the same size.  As 
expected, the Neu activation levels fluctuated despite the uniform size of tumors. These 
results suggested that the breast tumor is comprised of such a heterogeneous population 
that HER2/Neu may be not the only driving force in tumor growth. And this indicated the 
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possible crosstalk between HER2/Neu and other growth factor receptors such as PRLR, 




Fig. 4.1 Tyrosine phosphorylation of Neu (p-Neu) does not correlate with tumor 
size or tumor onset in female MMTV-neu transgenic mice 
Mammary tumors of varying size and metastatic lung tumors alng with normal 
surrounding tissue were resected from ten mice of the same age and made into lysates.  
(A) Western blot analysis shows no correlation between tumor size and p-Neu level (only 
representative data are shown).  p-Neu levels in metastatic lung tumors (LM) did not 
correlate with original mammary tumors (T).  Normal lung tissue (NL) expresses 
minimal Neu, if any.  (B) Ten mice with the same tumor latency were selected.  Normal 
mammary glands (MG) along with mammary tumors (T) in various sizes were resected 
from female MMTV-neu mice.  Western blot analysis suggests that no correlation 
between latency and p-Neu level (only representative data are shown).  No p-Neu was 
detected in normal mammary glands.  (C)  Eight female MMTV-neu mice with tumors of 
about the same size were resected and lysed.  Western blot shows the p-Neu levels 
fluctuate despite the uniform size of tumors. 
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Primary Tumor Cells Isolated from Mammary Tumors in Female MMTV-neu 
Transgenic Mice are Mostly Epithelial-Origin and Express Prolactin Receptors 
To further investigate mammary tumors from female MMTV-neu transgenic 
mice, tumors were allowed to grow to a certain size (1.5 cm in diameter) and were 
resected with sterile scalpels.  Samples were minced and processed into cell suspensions.  
A portion of primary cell suspensions were incubated with anti-EpCAM primary 
antibody conjugated with PE fluorochrome.  As an epithelial cell marker, EpCAM was 
found to be expressed in more than 99% primary tumor cells using FACS analysis (Fig. 
4.2). Therefore, we concluded that the primary tumor cells were mostly epithelial-origin. 
Another finding was that near 94% primary tumor cells expressed PRLR which laid the 




Fig. 4.2 Primary tumor cells isolated from mammary tumors in female MMTV-neu 
transgenic mice are mostly of epithelial-origin and express prolactin receptors 
Tumors were allowed to grow to a proper size (1.5 cm in diameter) and were 
resected with sterile scalpels.  (A) Samples were minced and processed into cell 
suspensions.  (B) A portion of primary cell suspensions were incubated wi h anti-
EpCAM (an epithelial cell component) primary antibody conjugated with PE 
fluorochrome.  FACS analysis indicates EpCAM is expressed in more than 99% primary 
tumor cells. (C and D).  Another portion of primary cell suspensions were incubated with 
anti-PRLR primary antibody conjugated with FITC fluorochrome.  FACS analysis shows 
up to 94% primary tumor cells express PRLR. 
 83
Inhibition of p-Neu by G129R is Dependent Upon Tumor Microenvironment in 
MMTV-neu Tumors 
Previous studies suggested that p-HER2 phosphorylation was enhanced by PRL 
[306] and inhibited by G129R [250] in T-47D and BT-474 human breast cancer epithelial 
cells.  In this project, the effects of PRL and G129R upon p-Neu wereexamined in a 
mouse model of HER2-positive breast cancer.  Tumors were resected from female 
MMTV- neu mice and processed into cell suspensions and tumor chunks.  The primary 
cell suspensions prepared from the tumor chunks were found to be almost entirely 
epithelial by flow cytometry (>99% EpCAM positive cells; mean fluorescence intensity 
>1700), which was visually confirmed upon examination of the cells 24 hrs afte  seeding 
on tissue culture plates (Fig. 4.2A).  Both primary cells and tumor chunks were depleted 
in DMEM supplemented with 0.5% charcoal stripped serum (CSS) and treated with 
G129R (10 and 50 µg/ml) or PRL (0.5 and 1 µg/ml) for 24 hrs before harvested.  In 
contrast to the previous experiments conducted using T-47D and BT-474 cells, G129R 
had little effect upon p-Neu level in the primary epithelial cels isolated from MMTV-neu 
tumors when cultured in monolayer (Fig. 4.3B); however, G129R inhibited p-Neu (Fig. 
4.3C) and PRL induced p-Neu (Fig. 4.3D) in a dose-dependent manner when the primary 
epithelial cells from the same tumors were maintained as tumor chunks. This obvious 
discrepancy between primary cell culture and tumor chunks suggested the inhibition of p-




Fig. 4.3 Inhibitory effect of G129R upon p-Neu is dependent upon tumor 
microenvironment 
Mammary tumors from MMTV-neu transgenic mice were split in two portions.  
One portion was digested with trypsin for monolayer culture in DMEM + 10% FBS.  (A) 
The other portion of the tumor was dissected into 3 mm3 chunks and cultured in serum-
free DMEM.  (B) Western blot analysis shows that G129R treatment (10 µg/ml, 50 
µg/ml, 24 hrs) has little effect on primary cells in monoculture.  In contrast, p-Neu is 
abrogated in tumor chunks in a dose-dependent manner.  (C) G129R and (D) PRL 
modulate the phosphorylation of Neu in tumor chunks.  All the experiments were 
repeated three times.  Paired t test was the method used for statistical analysis.  “*” means 
p value is less than 0.05, “**” means p value is less than 0.01. 
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In the Context with Tumor Microenvironment, G129R Exerts Additive Effect When 
Combined with Lapatinib 
Previously, we reported that G129R may exert an additive effect on the i hibition 
of HER2 over-expressing breast cancer cell lines when combined with trastuzumab.  
G129R was once again combined with an anti-HER2/Neu reagent, lapatinib.  Lapatinib is 
a small molecule tyrosine kinase inhibitor that blocks the kinase activity of HER1 and 
HER2 [204].  Data shows that lapatinib drastically reduces HER2 phosphorylation in SK-
BR-3 (Fig. 4.4A) and BT-474 (Fig. 4.4B) human breast cancer cell lines and Neu 
phosphorylation in mouse mammary tumor chunks in a dose-dependent manner with 
maximal suppression being observed at 10 µM (Fig. 4.4 and 4.5).  Lapatinib was clearly 
more potent than G129R in the inhibition of p-HER2/Neu.  Tumor chunks treated with 
lapatinib and G129R significantly reduced Neu activation, with the higher dose (10 µM 
lapatinib + 50µg/ml) almost completely nullifying p-Neu (Fig. 4.5).  The combination of 




Fig. 4.4 Lapatinib inhibits HER2 phosphorylation in SK-BR-3 and BT-474 cells 
SK-BR-3 and BT-474 breast cancer cell lines were monolayer cultured in RPMI 1640 
medium supplemented with 0.5% CSS before they were treated for 24 hrs.  (A) Western 
blot analysis indicates that lapatinib (0.1, 1, 10 µM) drastically reduces HER2 activation 
in SK-BR-3 cells.  (B) Western blot analysis indicates that lapatinib (10 µM) has an 
inhibitory effect on HER2 activation in BT-474 cells in the absence or presence of 
G129R; whereas, G129R (10, 50 µg/ml) alone fails to reduce p-HER2 levels.
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Fig. 4.5 In the context with tumor microenvironment, G129R exerts a additive 
effect when combined with lapatinib 
G129R and lapatinib are used in tumor chunk model.  (A) Western blots show 
lapatinib drastically reduces Neu phosphorylation in tumor chunks in a dose-dependent 
manner with a maximal suppression dose at 10 µM.  Lapatinib was cle rly more potent 
than G129R in the inhibition of p-Neu.  (B) Tumor chunks treated with lapatinib 
combined with G129R (1 µM lapatinib + 10 µg/ml G129R and 10 µM lapatinib + 50
µg/ml G129R) significantly reduced Neu activation, with the latter almost completely 
eliminatingp-Neu.
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Mouse and Human Breast Cancer Cell Lines Express Prolactin Receptors 
To make sure that the cell lines used in this study expressed PRLR, PRLR was 
examined in multiple breast cancer cell lines including T-47D, BT-474, SK-BR-3, and 
BT-483 human cell lines (Fig.4.6) and MCNeuA and N202Fb3 mouse cell lines (Fig. 
4.7A).  MCNeuA and N202Fb3 cells are epithelial and fibroblast cell lines, respectively, 
derived from the same mammary tumor of a female MMTV-neu transgenic mouse.  The 
cancer cell lines were seeded on glass slides and fixed with 10% neutral buffered 
formalin before being permeabilized in 10% Triton X-100.  Cells were treated with anti-
PRLR (H300) antibody and the UltraVision ONE Detection System HRP Polymer and 
DAB Plus Chromogen kit was used for immunohistochemistry.  HeLa cells w re used as 
a negative control.  As expected, PRLRs were expressed in all of the human breast cancer 
cell lines.  Detection of PRLR in MCNeuA and N202Fb3 cells was examined by both 
immunohistochemistry and immunoprecipitation followed by western blotting.  
Immunohistochemically, MCNeuA exhibited higher expression of PRLR compared with 
N202Fb3 cells (Fig. 4.7A).  For immunoprecipitation, approximately 1 mg of cell lysate 
was incubated with 5 µg of rabbit anti-PRLR (M170) (This antibody was raised against 
mouse PRLR) and 25 µl of protein G-sepharose.  Both cell lines expressed low level of 
PRLR compared with the expression level in T-47D cells (Fig. 4.7B). T47D, BT474, SK-
BR-3, BT483 and MCNeuA are breast cancer epithelial cell lines known for the 
overexpression of HER2/Neu. As expected, PRLR were co-expressed with HER2/Neu in 
all of these epithelial cells. 
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Fig. 4.6 Mouse and human breast cancer epithelial cell lines express olactin 
receptors at different levels 
SK-BR-3, T-47D, BT-474, BT-483 breast cancer cells were seeded on glass slides 
and fixed with 10% neutral buffered formalin and permeabilized in 10% Triton X-100.  
Cells were treated with anti-PRLR (H300) antibody and the UltraVision ONE Detection 
System HRP Polymer and DAB Plus Chromogen kit was to perform 
immunohistochemistry.  HeLa cells were used as a negative control.  




Fig. 4.7 MCNeuA and N202Fb3 cells express prolactin receptors at different lev ls
(A) MCNeuA and N202Fb3 cells were seeded together on glass slide  and fixed 
with 10% neutral buffered formalin before being permeabilized with10% Triton X-100.  
Cells were treated with anti-PRLR antibody raised against mouse PRLR and the 
UltraVision ONE Detection System HRP Polymer and DAB Plus Chromogen kit was 
used for immunohistochemistry (IHC).  IHC shows that both cell lines ar  able to express 
PRLR.  MCNeuA cells express higher levels of PRLR than N202Fb3 cells.  (B) Western 
blot analysis of PRLR in T-47D (positive control), MCNeuA, and N202Fb3 cells using 
40 µg of cell lysate and of immunoprecipitated PRLR starting with 1 mg of cell lysate.  
Data suggest that PRLR level in mouse cell lines is much lower than that in the human 
cell line, T-47D. 
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Co-cultured Breast Cancer Epithelial Cells and CAFs Exhibit Morphology Similar 
to Original Tumor 
This co-culture experiment was conducted to test if the discrepancy observed 
between the response to G129R in primary tumor cells and tumor chunks is due to the 
absence of tumor microenvironment components.  The importance of CAFs in mediating 
the inhibitory effect of G129R upon p-Neu was examined by directly co-culturing 
MCNeuA epithelial and N202Fb3 CAFs established from a spontaneous MMTV-neu 
mammary tumor.  Similar to what was observed in vivo, microscopic images revealed 
that the MCNeuA epithelial cells form islets surrounded by small nest-like clusters of 




Fig. 4.8 Co-cultured breast cancer epithelial cells and CAFs exhibits morphology 
similar to original tumor 
Microscopic images of MCNeuA (epithelial) cells and N202Fb3 (fibroblast) cells 
in monoculture or co-cultured at a 4:1 ratio.  MCNeuA cells and N202Fb3 cells were 
distinguished by using immunohistochemistry for E-cadherin and vimentin, respectively.  
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CAFs Modulate the Effect of G129R and PRL Upon p-Neu 
Treatment with G129R had a minimal effect, if any, on p- Neu when MCNeuA 
cells were grown alone in monolayer (Fig. 4.9); similar to what ws observed with 
primary epithelial cells.  To investigate the influence of CAFs upon p-Neu in tumor 
epithelial cells, direct co-culture experiments were conducted using different ratios (1:4, 
1:2, 1:1, 2:1, 4:1, or 8:1) of MCNeuA cells to N202Fb3 CAFs.  After 24 hrs treatment 
with G129R (10 µg/ml), a reduction in p-Neu was observed in cells seeded at a 2:1 and 
4:1 ratio (MCNeuA:N202Fb3), with the maximum reduction in p-Neu being observed at 
a 4:1 ratio (Fig. 4.9).  Time-course experiments revealed that the MCNeuA cells had to 
be co-cultured with N202Fb3 CAFs for at least 24 hrs prior to treatm nt in order to 
observe a reduction in p-Neu by G129R (10 µg/ml) (Fig. 4.10).  Under similar 
conditions, PRL (0, 0.1, 0.2, 0.5, 1.0, or 2.0 µg/ml) increased p-Neu in MCNeuA in a 
dose-dependent manner (Fig. 4.10B).  Fluctuations in p-Neu in response to G129R 
treatment were observed in different experiments.  Even though the ratios and courses of 
incubation were identical among co-culture experiments, the nest-lik  structures formed 
between the epithelial cells and fibroblasts were often of different size and shape.  Most 
of the variability observed in response to G129R is likely due to these obvious alterations 
in the interactions between the epithelial cells and fibroblasts.  Different cell passage 
numbers and lot-to-lot variability in culture medium, serum, and G129R may have also 
contributed to the variability. 
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Fig. 4.9 Fibroblasts in co-culture modulate the effect of G129R and PRL upon Neu 
phosphorylation 
Co-culture of MCNeuA and N202Fb3 cells at various ratios (1:4, 1:2, 1:1, 2:1, 4:1 or 8:1) 
were treated with G129R for 24 hrs.  Western blot analysis shows the inhibition of p- 
Neu by G129R is obvious at 2:1 and 4:1 ratio. All experiments were repeat d three times.  
Paired t test was used.  “*” means p value is less than 0.05. 
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Fig. 4.10 G129R inhibits and PRL induces p-Neu in co-culture after 24 hrs in a 
dose-dependent manner 
(A) MCNeuA and N202Fb3 cells were co-cultured at a 4:1 ratio and treated with 
G129R.  Treatments were terminated after 1, 5, or 24 hrs.  Western blot analysis shows 
that the maximal inhibitory effect of G129R upon p-Neu is observed at 24 hrs.  (B) 
MCNeuA and N202Fb3 cells were co-cultured at 4:1 ratio and were treated with various 
concentrations of PRL for 24 hrs.  Western blot results indicate th t PRL increases p- 
Neu in a dose-dependent manner.  All experiments were repeated thre  times.  Paired t 
test was used.  “*” means p value is less than 0.05. 
 97
In Co-culture, Normal Fibroblasts Possess Different Morphology From That of 
CAFs 
CAFs represent a group of fibroblasts in close proximity to cancer epithelial cells 
in tumors.  They are perpetually activated and are considered to be distinct from normal, 
non-activated fibroblast on many levels.  To test if the observation regarding the tumor 
fibroblast is truly CAF specific, I introduced two types of normal fibroblasts designated 
as NTG-MEF and NEU-MEF, derived from embryos of non-transgenic and MMTV-neu 
transgenic mice, respectively in similar co-culture experiment s tting.  In contrast to 
CAFs co-cultured with MCNeuA cells, co-culture of NTG-MEFs and NEU-MEFs both 
exhibited different morphology, characterized by larger cell processes (Fig. 4.11). Of 
note, in the coculture of MCNeuA and NTG-MEF cells, the formation of islets of 
MCNeuA was much less obvious than those observed in the coculture with N202Fb3 or 
NEU-MEF.  At this point, I am not sure if this morphological difference induced by 
N202Fb3 and NTG-MEF cells contributed to or determined the cross talk between the 
two receptors.  Nonetheless, it was an interesting observation. 
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Fig. 4.11 Co-culture of breast cancer epithelial cells and non-CAFs exhibits 
different morphology 
Microscopic images of MCNeuA (epithelial) cells co-cultured with mouse embryonic 
fibroblasts derived from a non-transgenic FVB mouse (NTG-MEF) or MMTV- neu 
transgenic mouse at a 4:1 ratio.  MCNeuA cells and MEFs were distinguished by using 
immunohistochemistry for E-cadherin and vimentin, respectively. 
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CAFs Have Properties Not Present in Normal Fibroblasts That Modulate the 
Effects of G129R and PRL Upon p-Neu 
Using the same direct co-culture system, it was further evaluated whether or not 
the inhibitory effect of G129R in MCNeuA cells which was restored by CAFs could be 
replaced by co-culture with normal embryonic fibroblasts i.e. CAFs were replaced with 
NTG-MEFs or NEU-MEFs.  However, treatment with G129R (10 µg/ml) for 24 hrs 
reduced p-Neu in MCNeuA cells co-cultured with N202Fb3 CAFs, but not in MCNeuA 
cells co-cultured with either of the MEFs (Fig. 4.12).  These results suggest that the 
modulation of G129R’s inhibitory effect on pHER2 in MCNeuA cells is CAF specific. 
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Fig. 4.12 The inhibitory effect of G129R upon epithelial cells vanishes when CAFs 
are replaced with normal fibroblasts in co-culture 
MCNeuA cells were directly co-cultured at a 4:1 ratio with N202Fb3 CAFs or 
with NTG-MEFs or NEU-MEFs derived from embryos of non-transgeic or Neu 
transgenic FVB/N mice, respectively.  The results show that G129R reduces p- Neu in 
MCNeuA cells only when co-cultured with N202Fb3 CAFs, but not when cultured alone 
or with NTG-MEFs or NEU-MEFs.  All experiments were repeated three times.  Paired t 
test was used.  “*” means p value is less than 0.05. 
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Modulation of the Cellular Signaling by Tumor Epithelial-Stromal Interactions 
Require Live Stromal Cells, Not Simply Cell Membrane Components 
To examine whether modulation of the cellular signaling in the epethilium 
requires live CAFs or mere cell membrane molecules, a predetermined amount of 
N202Fb3 cells were homogenized  Insoluble components containing cell membrane 
debris were collected and incubated with MCNeuA cells at a 2:1, 4:1 and 8:1 ratio 
(MCNeuA:N202Fb3, before grinding).  Treatment with G129R (10 µg/ml) for 24 hrs had 
no effect upon p- Neu (Fig. 4.13). 
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Fig. 4.13 Tumor epithelial-stromal interactions require live stromal cells, not simply 
cell membrane components 
MCNeuA cells were cultured with insoluble components of N202Fb3 cellsat a 
2:1, 4:1 and 8:1 ratio (MCNeuA:N202Fb3, before homogenization) and treated with 
G129R for 24 hrs.  Western blot results show mere cellular components of N202Fb3 cells 
do not sensitize MCNeuA cells to G129R. 
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Inhibition of p-Neu by G129R is Dependent Upon Tumor Epithelial-Stromal 
Interactions and Not Secreted Soluble Factors 
To determine if the influence of CAFs on G129R response was mediated by direct 
cell-cell and/or cell-matrix contacts, or via the secretion of soluble factors, MCNeuA 
cells and N202Fb3 CAFs were co-cultured together or in close proximity separated by a 
permeable membrane.  Using the transwell system, MCNeuA cells w re placed in the 
bottom chamber and N202Fb3 CAFs were placed on the transwell insert; treatment with 
G129R (10 µg/ml) for 24 hrs had no effect upon p-Neu in the absence of cell-cell and/or 
cell-matrix contact (Fig. 4.14).  
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Fig. 4.14 The inhibitory effect of G129R upon epithelial cells vanishes when CAFs 
are separated from epithelial cells using a transwell culture system 
MCNeuA cells were seeded in the bottom chamber of a 6-well transwell system 
and cultured with or without N202Fb3 cells on the insert at a 4:1 ratio or they were 
directly co-cultured with N202Fb3 cells prior to treatment with G129R for 24 hrs.  
Western blot results show that MCNeuA cells do not respond to G129R when cultured 
alone or when physically separated from N202Fb3 cells.  All experiments were repeated 
three times.  Paired t test was used.  “*” means p value is less than 0.05.   
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G129R Reduces p-Neu Level In Vivo 
To assess the efficacy of G129R in vivo, a self comparison model was developed 
using pre- and post-treatment tumor biopsy samples to compare the levels of p-
HER2/Neu before and after treatment with G129R.  Spontaneous tumors arising in 
female MMTV-neu mice were allowed to reach approximately 1 cm in diameter before 
tumor biopsy.  Two days after biopsy, mice were treated with various d ses of G129R for 
five or ten days.  Approximately 24 hrs following the final treatment the tumors were 
removed.  Phospho- Neu was reduced by G129R treatment in a dose-dependent manner,
with a noticeable reduction seen with 5 mg/kg/day dose and maximal reduction seen with 
10 mg/kg/day dose (Fig. 4.15).  The inhibitory effect of G129R upon p-Neu was 
observed in as few as 5 days and was sustained after 10 days of treatment (Fig. 4.16). 
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Fig. 4.15 G129R inhibits p-Neu in spontaneous MMTV-neu tumors in vivo 
(A) Pre- and post-G129R treatment biopsy samples were used for dose- esponse 
analysis and p- Neu was assessed by western blot.  (B) Pre- and post-G129R treatment 
biopsy samples were used for time-course analysis and p-Neu was asse sed by western 
blot.  All experiments were repeated three times. 
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Having optimized the dose of G129R (10 mg/kg/day), the response to G129R was 
tested on a greater number of mice.  Fourteen mice with spontaneus tumors received a 
5-day treatment of G129R (10 mg/kg/day, i.p.) with the goal to reduce p-Neu.  Five mice 
were highly responsive, four were moderately responsive, and five were unresponsive, 
with a total response rate of 64% (9/14).  Ten mice received a 10-day treatment of G129R 
(10 mg/kg/day, i.p.) with the goal to reduce p-Neu.  Tumors from three mice were highly 
responsive, five were moderately responsive, and two were unresponsive, with a total 
response rate at 80% (8/10).  A portion of the results for the 5-day and 10-day G129R 
treatments are shown (Fig. 4.16). 
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Fig. 4.16 G129R reduced Neu phosphorylation in tumors from randomized MMTV-
neu mice 
Tumor-bearing MMTV-neu mice were randomized into Vehicle or G129R 
(10mg/kg/day) treatment groups.  Mice were treated for 5 or 10 days.  Approximately 24 
hrs after the final injection, tumors were removed and p-Neu was assessed by western 
blot. 
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In the Presence of CAFs, G129R Exhibits Synergistic Effect When Combined With 
G120R 
G120R is a human growth hormone antagonist where the glycine at position 120 
is substituted by arginine in native 22-kDa human growth hormone.  G120R impairs 
normal dimerization of the growth hormone receptors activated by growth hormone.  A 
study indicated in breast cancer cells, co-treatment with the combination of G120R and 
G129R inhibited GH-induced STAT5 and JAK2 activation more effectively than either 
antagonist individually.  Therefore, a similar treatment of the combination of G120R and 
G129R was used in both MCNeuA monocultured cells and MCNeuA cells co-cultured 
with N202Fb3 CAFs.  As expected, cancer cells did not respond to the treatment in 
monoculture; whereas, the p-HER2 in epithelial cells in co-culture was largely inhibited 




Fig. 4.17 In the presence of CAFs, G129R exhibits a synergistic effet when 
combined with G120R 
Monocultures of MCNeuA cells or co-cultures of MCNeuA cells with N202Fb3 
CAFs were treated with G129R (10 µg/ml), G120R (10 µg/ml) or combinations of both.  
After 24hr, cells were harvested and analyzed by western blot. MCNeuA cells did not 
respond to treatments in monoculture; whereas, p-Neu was largely inhibited by the co-
treatment in co-culture. 
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Co-culture Model Also Applies to Human Cell Lines 
Since the human breast cancer cell line, SK-BR-3, expresses high levels of both 
HER2 and PRLR, it was selected to examine the validity of the co-culture model with 
human cell lines.  A human CAF cell line derived from an invasive ductal breast 
carcinoma in a 49 year-old Caucasian female was also selected.  Tr atment with G129R 
for 24 hrs had a minimal effect, if any, on p-HER2 when SK-BR-3 cells were grown 
alone in monolayer.  When SK-BR-3 cells were co-cultured at a 4:1 ratio with human 
CAFs, a reduction in p-HER2 was observed after 24 hrs treatment with G129R (10 
µg/ml) (Fig. 4.18A).  A similar response was observed when SK-BR-3 cells were co-
cultured with mouse N202Fb3 CAFs, indicating that CAFs derived from mice or humans 




Fig. 4.18 G129R reduces p-HER2 in SK-BR-3 cells when co-cultured with CAFs 
(A) SK-BR-3 cells were co-culture at a 4:1 ratio with primary CAFs derived from 
a human invasive ductal breast carcinoma and treated with G129R for 24 hrs.  Western 
blots for p-HER2 shows that co-culture restores cell response to G129R in SK-BR-3 
human breast cancer cells.  (B) SK-BR-3 cells were co-cultured at a 4:1 ratio with mouse 
CAFs (N202Fb3 cells) or primary embryonic fibroblasts (NEU-MEFs and NTG-MEFs) 
and treated with G129R for 24 hrs.  Western blots for p-HER2 indicates that only 
N202Fb3 cells restored response to G129R in human breast cancer cell lines. 
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The Mediator of CAFs Interaction With Certain Epithelial Cells May Lie in ECM 
In the effort to explore the molecular mechanism behind the interaction between 
the CAFs and cancer epithelial cells, I already excluded soluble factors selected by CAFs, 
components on the cell membrane in CAFs and normal fibroblasts derived from embryos.  
Therefore, my next step was to examine the ECM.  The culture was maintained for 4 ays 
before treatments were carried out.  In matrigel culture with MCNeuA cells, Neu 
phosphorylation was clearly suppressed by G129R and up-regulated by PRL both in a 
dose-dependent manner (Fig.4.19A).  In matrigel culture with SK-BR-3 cells, PRL 
seemed to have minimal stimulatory effect upon p-HER2 (Fig.4.19B).  However, G129R 
still exhibited an evident down-regulation on p-HER2. Interestingly, BT-474 in matrigel 





Fig. 4.19 The mediator of CAFs interaction with certain epithelial cells may lie in 
ECM 
Matrigel was used to pre-coat the 12-well plates to form a thin layer at the bottom. 
MCNeuA, SK-BR-3 and BT-474 cells (1 x 105cells/well) were suspended in the mixture 
of DMEM (500 µl/well) and EHS (120 µl/well) and placed onto the coated surface.  The 
cell mixture was allowed to settle and attach to the EHS at the bottom before another 500 
µl DMEM and 120 µl matrigel were added on top of the gel and the culture was 
maintained for 4 days before treatments were carried out.  Colonies f mouse and human 
breast cancer cell lines formed in Matrigel were treated with PRL or G129R for 24 hrs.  
(A) Western blots show that Neu phosphorylation is clearly suppressed by G129R and 
up-regulated by PRL in a dose-dependent manner in MCNeuA cells.  (B) Western blots 
show that PRL has little stimulatory effect upon p-HER2; whereas, G129R down-regulats 
p-HER2 in SK-BR-3 cells.  (C) Western blots show that BT474 cells do not respond to 
PRL or G129R treatments. 
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HER2 Positive Breast Cancer 
It is known that HER2 gene is amplified in approximately 20 to 30% of breast 
cancers patients [196, 282].  HER2-overexpressing breast cancers are marked with a poor 
prognosis and fewer successful therapeutic options [122, 258]. 
The two main signaling pathways in HER2 activation include PI3K-AKT and 
RAS/MAPK pathway (Fig. 5.1).  In RAS/MAPK pathway, after tyosine receptors are 
phosphorylated, the adaptor molecules GRB2 and/or SHC bind to the carboxyl tail of the 
receptor through SH2 domains [83, 223].  The guanine-nucleotide exchange factor, SOS, 
next interacts with SHC/GRB2 via the GRB2 SH3 domain, and this complex is brought 
to the receptor at the cytoplasmic surface of the plasma membrane.  SOS subsequently 
catalyzes the dissociation of GDP from RAS, permitting the formation of an activated 
RAS-GTP complex [185].  RAS-GTP then activates RAF-1, a serine-threonine kinase.  
RAF-1 in turn phosphorylates and activates MEK, a specific threonine-tyrosine kinase 
which activates MAPK [173].  In T-47D human breast cancer cells, which express all 
four members of the class I RTK family, SHC phosphorylation and MAPK activation 
occur after treatment with NDF.  The degree of MAPK activation is markedly reduced, 
however, when HER2 expression is decreased by single-chain antibody-mediated 
intracellular retention of the molecule in the endoplasmic reticulum [117]. 
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Another pathway is PI3K/AKT.  It is acknowledged that HER2 induces 
transformation through PI3K/AKT pathway in cooperation with HER3 [8, 133].  Data 
indicates that HER2 is a favorable heterodimeric partner for HER3.  Through this 
heterodimerization, HER3 provides HER2 the p85 binding motifs to PI3K [231, 260].  
This is further supported by that tumors from MMTV-neu mice and HER2 
overexpressing human breast tumor have activation of PI3K signaling [9, 274, 315].  The 
activation of PI3K/AKT regulates numerous cellular functions in cancer cells including 
cell proliferation and survival, cell size and response to nutrient availability, glucose 
metabolism, epithelial-mesenchymal transition and cell invasiveness, genome stability, 
and angiogenesis [191, 220, 271, 284]. 
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Fig. 5.1 Illustration of HER2 pathway [177] 
In RAS/MAPK pathway, after tyrosine receptors are phosphorylated, GRB2 
interacts with SOS.  SOS subsequently catalyzes the dissociation of GDP from RAS, 
permitting the formation of an activated RAS-GTP complex. RAS-GTP then activates 
RAF-1. RAF-1 in turn phosphorylates and activates MEK, which activates MAPK; In 
PI3K/AKT pathway, the dimerization of HER2/HER3 activates PI3K/AT which in turn 
regulates cell survival and apoptosis through GSK and Bad. 
 119
 
To date, there are two drugs designed to target HER2 approved by FDA for the 
treatment of HER2-positive breast cancers, trastuzumab and lapatinib.  Trastuzumab is a 
humanized monoclonal antibody which is consided as the first targeted therapy for the 
management of HER2-positive metastatic breast cancers.  Trastuzumab has synergistic 
effect when combined with a variety of chemotherapy drugs. Trastuzumab is also 
beneficial when combined with endocrine therapy in both ER and HER2-positive patients 
[156].  Unfortunately, the majority of patients that initially respond to treatment develop 
resistance resulting in disease progression [285].  The relative refractory state of these 
HER2-positive breast carcinomas illustrates the need to examine the mechanisms 
underlying tumor drug resistance and the necessity to examine novel combinations with 
other agents.   
Lapatinib, a small molecule tyrosine kinase inhibitor that blocks the kinase 
activity of HER1 and HER2 is found to be able to help patients to overcom so e 
trastuzumab resistance [204].  It has been used as a treatment for ER+/EGFR+/HER2+ 
breast cancer patients (now often called "triple positive") and in patients who have 
HER2-positive advanced breast cancer that has progressed after previous treatment with 
other chemotherapeutic agents, such as anthracyline, taxane-derived drugs, o  
trastuzumab. In clinical study, this drug has been shown to cause remissions in 
trastuzumab-resistant patients and it may be more effective when given together with 
trastuzumab [36, 263].  Being stated that, however, HER2-positive breast cancer is still 
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one of the most difficult subtypes of breast cancer to tackle. Therefor , it is significant to 
have a better understanding of HER2/Neu signaling pathways through a bi ger picture, 
i.e. not only examing its intrinc molecular events upon various stimuli, b t also dissect its 
responses in the context of tumor microenviroement. 
HER2 and PRLR Cross Talk 
First of all, HER2 is not the only player in HER2 positive breast c ncer. Many 
clinical studies investigated the association of HER2 overexpression with breast tumor 
size. In a group of 209 consecutive female patients with invasive operable breast cancer 
from a defined urban population observed for a median of 30 years, western blots 
suggested HER2 expression was related to the ductal histologic type, poor histologic 
grade, and high mitotic count, but not to tumor size, axillary nodal status [273].  This is 
consistent with my study.  In the group of 10 mice with mammary tumors in different 
sizes, I observed no correlation between tumor size and Neu phosphorylation level.  Also 
p-Neu levels in metastatic tumors in lungs did not appear to be consistent with that in 
original tumors.  In another group of 10 mice with the same tumor onset, no correlation 
was observed between tumor onset and Neu phosphorylation level. 
These results could be potentially explained by the heterogeneity of tumor cells in 
breast cancer.  It is obvious that HER2/Neu is not the only driving force in tumor growth.  
The presence of other growth factor receptors such as ER, PR or PRLR could also play a 
role in tumor growth via their own tumorigenic mechanism as well as cross talk with 
HER2/Neu.  Simply, a HER2-positive and PRLR-negative tumor would be less 
 121
aggressive than a HER2-positive and PRLR-positive tumor.  As a result, the 
characteristics of breast tumors are determined by the synergistic effect of the 
overexpression of HER2 and other receptors instead of by the effect of any single factor. 
In addition, it was demonstrated that HER2/Neu and PRLR were found to be c -
expressed in breast tumors and various breast tumor cell lines.  I primary tumor cells 
isolated from breast tumor derived from female MMTV- neu transgenic mice, the FACS 
analysis indicated that EpCAM was found to be expressed in more than 99% primary 
tumor cells, nearly 94% of which also expressed PRLR.  Also, immunoprecipitation 
detected PRLR expression in both MCNeuA and N202Fb3 cells derived from breast 
tumor of a female MMTV-neu transgenic mouse, though the expression level was far 
lower than that in T-47D human breast tumor cells.  Additionally, immunohistochemistry 
showed a high level of PRLR expression in human cell lines that also overexpress HER2, 
such as SK-BR-3, T-47D, BT-474 and BT-483.  Consistently, in an earlier study in our 
lab, PRLR and HER2 were detected in all four ductal carcinoma cell lines (BT-474, 
MDA-MB-134, BT-483, T-47D) and two of the six cell lines isolated from pleural 
effusions (SK-BR-3, MDA-MB-453).  Expression of PRLR or HER2 was low or near 
absent in four of the cell lines isolated from pleural effusions (MCF-7, MDA-MB-468, 
MDA-MB-436, and MDA-MB-231) [250]. 
Furthermore, varied effects of phosphorylation dependent cross talk have been 
noted for PRLR and other growth factor receptors.  Sheffield and colleagues 
demonstrated that PRL caused modest MAPK activation and PRL treatment resulted in 
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EGFR threonine phosphorylation in the normal murine mammary epithelial cells
(NMuMG) model system [91-92, 149, 234].  In the NMuMG cells, PRL decreased both 
basal and EGF-induced EGFR tyrosine kinase activity.  Furthermore, PRL co-treatment 
dramatically inhibited EGF-induced RAS/MAPK signaling and EGF-induced 
mitogenesis.  In contrast, the Clevenger laboratory demonstrated that several human 
breast cancer cell lines including T-47D, MCF-7 and MDA-MB-231 exhibited 
synergistically increased motility when treated with the combination of PRL and EGF 
compared to the sum of responses to each individual factor [194]. 
The first study demonstrating the cross talk between HER2 and PRLR was done 
by a Japanese group in 2000. Yamauchi et al. reported that human breast carcinomas 
overexpressing HER2 have higher proliferative and metastatic activity in the presence of 
autocrine PRL.  They used a neutralizing antibody or dominant negativ  (DN) strategies 
or specific inhibitors to show that activation of JAK2 by autocrine secretion of PRL is 
one of the significant components of constitutive tyrosine phosphorylation of HER2, its 
association with GRB2 and activation of MAPK in human breast cancer cell lines that 
overexpress HER2 (Fig. 5.2).  Furthermore, the neutralizing anti-PRL antibody or HER2 
antisense oligonucleotide or DN-JAK2 or JAK2 inhibitor or DN-RAS or MAPK inhibitor 
inhibits the proliferation of both untreated and PRL-treated cells.  The conclusion was 
drawn that autocrine secretion of PRL stimulates tyrosine phosphorylati n of HER2 by 
JAK2, provides docking sites for GRB2 and stimulates RAS-MAPK cascade, thereby 
causing unrestricted cellular proliferation [306].  Similar to what they observed, our 
previous study examined the phosphorylation status of HER2 and activation of MAPK, 
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STATs, as well as PI3K-AKT signaling cascades in response to trastuzumab, G129R or a 
combination of the two in either the absence or presence of exogenous PRL.  As a single 
agent, trastuzumab was more effective than G129R at inhibiting AKT phosphorylation; 
whereas, G129R was superior at blocking STAT3 and STAT5 activation.  G129R was 
also able to directly inhibit the HER2 phosphorylation.  Additionally, the combination of 
trastuzumab and G129R had an additive inhibitory effect on HER2 and MAPK 
phosphorylation, confirming that the MAPK signaling is a converging pathw y shared by 
both HER2 and the PRLR.  Finally, the combination of trastuzumab and G129R also 
additively inhibited cell proliferation in vitro and in vivo as measured by inhibition of the 
growth of T-47D and BT-474 xenografts in athymic nude mice [250].  
In this dissertation, MMTV-neu mice bearing spontaneous tumors were used as a 
model of HER2 breast cancer to further examine the efficacy of G129R.  Compared to 
pretreatment tumor biopsies, G129R decreased p-Neu in a dose- and time- ependent 
manner after 5 days of treatment and p-Neu was nearly abolished after 10 days of 
treatment in a majority of the mice.  Likewise, p-Neu was reduced in the group of mice 
randomized to receive G129R (10 mg/kg/day) compared with the group that received the 
Vehicle.  Similar to the in vivo studies, but to a lesser extent, G129R (10 µg/ml) was able 
to reduce p-Neu in cultured tumor chunks; however, it had no effect on monocultures of 
primary epithelial cells or an epithelial cell line (MCNeuA) derived from a spontaneous 
mammary tumor of an MMTV-neu mouse.  These results suggest that cross talk between 











Fig. 5.2 Demonstration of the cross talk between HER2 and PRLR 
The activation of Janus kinase (JAK2) by autocrine secretion of PRL is one of the 
significant components of constitutive tyrosine phosphorylation of HER2.  It initiates the 
association with GRB2/SOS/RAS and activation of MAPK in human breast cancer cells. 
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Cancer-Associated Fibroblasts and Extracellular Matrix 
Tumor microenvironment is mainly consisted of CAFs, immune cells, endothelial 
cells and the surrounding extracellular matrix secreted primarily by CAFs. Under normal 
conditions, stroma and epithelia are separated by basement membrane in mammary tissue. 
However, in the event of carcinogenesis, the abnormally growing tumor epithelial cells 
break through the basement membrane and invade into the surrounding stroma. This 
allowed the aberrant activation of the pre-existing communication in the form of soluble 
factors secreted by both tissues while the direct cell-cell contact between tumor epithelia 
and stroma is also achieved. According to a number of references, CAF  is one of the key 
components participating in these carcinogenic events. Therefore, CAFs could paly an 
important role enhancing the crosstalk between HER2 and PRLR.  
In this dissertation, it was demonstrated that the response to G129R and PRL 
could be restored when MCNeuA cells were co-cultured with N202Fb3 CAFs and that 
replacement of CAFs with normal NTG-MEFs or NEU-MEFs failed to reduce p-Neu in 
response to G129R.  Considering that MCNeuA cells and N202Fb3 CAFs were derived 
from the same mammary tumor of a female MMTV-neu transgenic mouse, it was clear 
that adding back CAFs, at least partially, reconstituted the original tumor 
microenvironment which remains intact in tumor chunks and in the tumors in vivo.  
Similar results were observed using human cells, G129R had no effect upon p-HER2 in 
SK-BR-3 cells when grown in monoculture or co-culture with normal NTG-MEFs or 
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NEU-MEFs.  Cross talk between the PRLR and HER2 was only observed when SK-BR-3 
cells were co-cultured with human CRL-7,236 CAFs or mouse N202Fb3 CAFs.  
So what is the molecular mechanism behind this epitheli-stromal interaction? 
What is so unique in CAFs that mediates the cross talk between PRLR and HER2 while 
other normal fibroblasts fail?  
It has been known that CAFs are perpetually activated fibroblasts at the site of the 
tumor.  These cells are thought to be originated from not only local normal fibroblasts, 
but also bone marrow-derived cells, malignant epithelial cells, and endothelial cells [39, 
152, 312].  CAFs directly stimulate tumor cell proliferation by contribu ing various 
growth factors, hormones and cytokines (Fig. 5.3).  Classical mitogens for epithelial 
cancer cells, such as hepatocyte growth factor, epidermal growth factor, fibroblast growth 
factor, are all vastly expressed by CAFs contacting different tumor types.  Beside growth 
factors, pro-inflammatory cytokines, such as interleukins, interferons and members of the 
tumor necrosis factor family, are produced both by stromal and ccer cells, and exert 
tumor-modulating effects, such as SDF-1, CXCL14, CCL7, and IL-6 [236]. This 
expression by CAFs of cytokines and chemokines leads to immune cell infiltration that in 
turn promotes angiogenesis and metastasis [106]. On the other hand, CAFs synthesize 
many of the constituents of the fibrillar ECM such as type I, type III and type V collagen, 
and fibronectin [238, 275].  They also contribute to the formation of basement 
membranes by secreting type IV collagen and laminin [48]. 
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Fig. 5.3 Interplay between CAFs and tumor cells 
Tumor progression needs a positive and reciprocal feedback between CAFs and 
cancer cells.  Cancer cells induce and maintain the fibroblasts activated phenotype which, 
in turn, produce a series of growth factors and cytokines that sustain tumor progression 
by promoting ECM remodelling, cell proliferation, angiogenesis and EMT [53]. 
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The ECM is composed of an interlocking mesh of fibrous proteins and 
glycosaminoglycans (Fig. 5.4).  The important molecular components include heparin 
sulfate (HS), collagen, fibronectins and laminins.  HS is a linear polysaccharide that binds 
to a variety of protein ligands and regulates a wide variety of bi logical activities, 
including developmental processes, angiogenesis, blood coagulation and tumor 
metastasis.  Collagen is a large molecule composed of a triple helix, which generally 
consists of two identical chains (α1) and an additional chain that differs slightly in its 
chemical composition (α2).  The common types of collagen are fibrillar collagen (Type I, 
II, III, V, XI) and basement membrane (Type IV).  Fibronectins are proteins that connect 
cells with collagen fibers in the ECM, allowing cells to move through the ECM.  
Fibronectins bind collagen and cell surface integrins, causing a reorganization of the 
cell's cytoskeleton and facilitating cell movement. Laminins form networks of web-like 
structures that resist tensile forces in the basal lamina.  They also assist in cell adhesion.  
Laminins bind other ECM components such as collagens, nidogens, and entactins [229]. 
Therefore, there are at least two forms of interaction between epithelium and 
stroma in cancer. One is through the communication of soluble bioactive factors secreted 
by CAFs and tumor epithelial cells (Fig. 5.3). The other form is through the direct cell-
cell contact. This cell-cell contact is primarily mediated by extracellular matrix produced 
mainly by CAFs.  
To differentiate the effects bridged in the precence of CAFs is solulable factors or 
insolable, large ECM components produced by CAFs, an experiment using a transwell 
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system was conducted to physically separate MCNeuA cells from N202Fb3 CAFs, yet 
still allow soluble secreted molecules to permeate back and forth between the cells. 
G129R had no effect on p-Neu in the absence of cell–cell and/or cell–matrix contacts, 
suggesting that the bioactive molecule is not a soluble growth factor.  On the other hand, 
MCNeuA cells cultured with physically disrupted membrane components of N202Fb3 
CAFs did not restore cross talk between PRLR and HER2, suggesting that the interaction 
between tumor epithelia and stroma required CAFs to be alive.  Through the process of 
elimination, I speculate that PRL and G129R modulate the expression of a ECM 
component by CAFs and that this ECM component enables cross talk between the PRLR 




Fig. 5.4 Illustration of extracellular matrix 
The ECM is composed of an interlocking mesh of heparin sulfate (HS), collagen, 
fibronectins and laminins.  Integrin, the transmembrane receptor is the main cell surface 
receptor interacting with the ECM [150]. 
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After excluding soluble factors selected by CAFs, components on the cell 
membrane in CAFs and normal fibroblasts derived from embryos. The ECM using 
matrigel was examined. Matrigel is the trade name for a gel tinous protein mixture 
secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells and marketed by BD 
Biosciences.  This mixture resembles the complex extracellular environment found in 
many tissues and is used by cell biologists as a substrate fo  cell culture.  Matrigel, which 
primarily consists of laminin, collagen IV, heparan sulfate proteoglycans, and enactin, is 
considered to be a reconstituted basement membrane preparation.  The growth factor 
reduced (GFR) used in the project is a version of matrigel that has been modified to 
reduce abundance levels of these growth factors including basic fibroblast growth factor, 
epidermal growth factor, IGF-I, TGF-β, platelet-derived growth factor, and nerve growth 
factor.  The method used to prepare this product effectively reduced the level of a variety 
of growth factors except for TGF-β which may be bound to collagen IV and/or 
sequestered in a latent form that partitions with the major components in the purification 
procedure [139]. 
In matrigel culture with MCNeuA cells, Neu phosphorylation was suppressed by 
G129R and up-regulated by PRL both in a dose-dependent manner.  In matrigel culture 
with SK-BR-3 cells, PRL seemed to have minimal stimulatory effect in p-HER2. 
However, G129R still exhibited an evident down-regulation on p-HER2.  Interestingly, 
BT-474 in matrigel failed to respond to any of the treatments.  
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Taking all the results together, I believe that an additional mechanism responsible 
for the cross talk between the PRLR and HER2, especially in MCNeuA c lls, should be 
considered, which is different from the one reported previously using traditional 2D cell 
cuture system.  Fast and sustained stimulation of p-HER2 and p-MAPK has been reported 
to occur in response to PRL in human breast cancer cell lines in theabsence of CAFs, 
which is dependent upon the kinase activity of JAK2 to recruit the association of GRB2 
with HER2; likewise, a reduction in p-HER2 and p-MAPK has been report d to occur in 
response to anti-PRL and G129R in human breast cancer cell lines in the absence of 
CAFs [250, 306].  In my experiment, the modulation of p-Neu in MCNeuA cells and to a 
less extent in SK-BR-3 cells required the presence of CAFs and was not observed in their 
absence.  It should be noted that the means by which p-HER2 was analyzed in SK-BR-3 
cells differed between my study and that of Yamauchi et al. [306].  They analyzed p-
HER2 by immunoprecipitating HER2 and western blotting for total tyrosine 
phosphorylation; whereas, I blotted for the phosphorylation of the C-terminal tyrosine 
residue of HER2/Neu that has been reported to serve as docking site for adapter proteins 
that modulate MAPK activity and to be necessary for Neu-induced transformation and 
HER2-induced cell migration [22, 79].  Also, in contrast to this rapid moulation of p-
HER2 by PRL in human breast cancer cells, the cross talk observed was delayed.  
Inhibition of p-Neu in response to G129R in co-cultured MCNeuA cells and inhibition of 
p-HER2 in co-cultured SK-BR-3 cells was not significant until approximately 24 hrs after 
treatment.  Since the cross talk observed between the PRLR and HER2/Neu required 
CAFs and took longer to observe, it would appear to be via a different mechanism than 
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the one previously reported to occur in monocultures of human breast cancer ell lines.  I 
speculate that G129R is inhibiting, and PRL is stimulating, the synthesis of a bioactive 
molecule in ECM by CAFs that modulates p-HER2/Neu. Another possibility is that the 
delay is due to the process of forming certain structure, i.e. formation of 3D structure or 
even CAFs specific 2D structure as I noted in my co-culture experiments which 
compared the different fibrobalsts.  
It should be noted that considerable variability was observed in the reduction of p-
Neu in response to G129R (~20–50%) even though the ratio of MCNeuA cells to 
N202Fb3 cells (4:1) and course of incubation with G129R (10 µg/ml) were identical 
among many of the co-culture experiments.  Some of this variability may be attributed to 
fluctuations in the proliferation rates among the MCNeuA cells and N202Fb3 CAFs, 
which resulted in morphological changes in the size and shape the nest-like structures 
formed between the cells, and reflects an alteration in the interactions between the 
epithelial cells and CAFs.  Since G129R reduced p-Neu significantly at a 4:1 ratio but not 
at an 8:1 ratio, larger nest-like structures formed because of excessive MCNeuA cell 
proliferation may have reduced the critical interactions with CAFs.  A net reduction in p-
HER2 was observed when SK-BR-3 cells were incubated with MEFs because of 
alterations in proliferation. SK-BR-3 cells proliferated more slowly in the presence of 
MEFs than CAFs resulting in large nests of fibroblasts surrounding small islets of SK-
BR-3 cells.  The largest variable appears to be due to differences i  ll passage numbers, 
particularly in the CAFs.  Many of my late passage N202Fb3 cells lost the ability to 
modulate p-Neu in MCNeuA cells.  I speculate that these variables alter the synthesis and 
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deposition of an ECM component by the CAFs, necessary for cross talk between the 
PRLR and Neu. 
Possible Cellular and Molecular Mechanism  
I believe direct interactions with ECM components in the tumor 
microenvironment may activate cell adhesion molecules, such as the integrins, and result 
in the activation of signal transduction pathways [137]. Many literatures showed that 
integrins were actively involved in carcinogenesis in the form of interacting with ECM 
components. Meanwhile, integrins were also involved in both PRLR and HER2 activities.  
A study has shown that the integrin-mediated adhesion to ECM components 
modulates the responsiveness of epithelial cells to PRL.  Interaction of β1-integrin with 
the basement membrane component laminin 1 modulates the ability of PRL to stimulate 
STAT5 DNA-binding activity and express milk proteins, while the interaction of the 
same integrin with the stromal component collagen I does not [3, 265, 317]. Clevenger et 
al. demonstrated that following PRL stimulation, a complex between the transmembrane 
glycoprotein signal regulatory protein-α (SIRPα) and the PRLR, β1-integrin, and JAK2 in 
estrogen receptor-positive and negative breast cancer cells is formed.  Overexpression of 
SIRPα in the presence of collagen 1 increased PRL-induced gene expression, 
phosphorylation of JAK2, STAT5, and MAPK, and PRL-stimulated cell growth.  T is 
indicated interactions between the PRLR/β1-integrin complex and collagen I modulate 
the responsiveness of breast cancer cells to PRL and to contribute to br ast cancer 
progression [103].  Furthermore, Giancotti et al. reported ex vivo studies that indicate 
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beta 4 forms a complex with Neu and enhances activation of the transcription factors 
STAT3 and c-Jun. In vivo, loss of beta 4 signaling suppresses mammary tumor onset and 
invasive growth and enhances the efficacy of Neu-targeted therapy.  These results 
indicate that beta 4 integrin promotes tumor progression by amplifying Neu signaling 
[121].   
Putting these all together, therefore, I speculate that the cell and environmental 
interactions mediated by integrins in tumors may play an important role in inducing cross 
talk between PRLR and HER2/Neu on certain tumor cells and influence their 
responsiveness to therapeutic agents such as G129R. 
3D structure 
Since the matrigel culture system allowed tumor epithelial cells grow into spheres, 
I can not exclude the possibility that in this assay, the enhancement in the crosstalk 
between PRLR and HER2 could be induced by the change in cell behavior promoted by 








In summary, I demonstrate that CAFs, but not normal fibroblasts, play an 
important role in modulating the cross talk between PRLR and HER2/Neu.  The 
inhibitory effect of G129R on p-HER2/Neu in tumor epithelial cells depends on, to a 
certain degree, direct contact with CAFS.  My evidence further suggests that the cross 
talk between the two receptors is likely enhanced by insoluble ECM components 
produced by CAFs, which probably explained why G129R is more effective in 
decreasing p-Neu in spontaneous MMTV-neu mouse mammary tumors in vivo and in cell 
culture.  My result suggests that monoculture models may have poor pre-clinical 
predictive value for certain drug response.  The significance of this inding is that caution 
must be taken when extrapolating the clinical benefits of drugs using monocultured breast 
cancer cell lines because of fundamental differences in cell behaviors between 
monoculture and co-culture systems in the context of tumor microenvironment.  The 
direct co-culture model and in vivo studies highlight the significant difference in response 
to PRL and G129R when compared to monoculture systems, further proving the 
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